Drug, bio-affecting and body treating compositions inventions 12/07

20070297987 - Anti-adhesion sheet: An anti-adhesion sheet for placement upon the anterior wall of a vertebral body, wherein the sheet has a radius of curvature that is less than that of the anterior wall of the vertebral body.... Agent: Philip S. Johnson Johnson & Johnson

20070297988 - Optical probes for in vivo imaging: Disclosed is an image probing conjugate. The conjugate comprises a nanoparticle and a targeting agent. The nanoparticle comprises a dye which is encapsulated by a functionalized polymer, and the targeting agent is bound to the functional group of the polymer. The nanoparticle provides the conjugate with improved stability and an... Agent: Bin Wu

20070297990 - Self-preserving composition: The invention provides self-preserving compositions and methods for their production.... Agent: Darryl C. Little Attorney For Applicant

20070297991 - Neural conduit agent dissemination for smoking cessation and other applications: A method for disseminating nicotine or another agent using a neural conduit for direct transport from a peripheral nervous system site of administration to a central nervous system site of operation. In one embodiment, the agent may be provided to a sensory organ, such as the nose, for dissemination along... Agent: Thompson Hine L.L.P. Intellectual Property Group

20070297996 - Multi-phase composition comprising a sunscreen: Personal care composition comprising a discrete transparent aqueous phase and a discrete non-aqueous phase, wherein the aqueous phase comprises from about 0.05% to about 5% of a polymeric thickener, and from about 50% to about 99.5% water, both by weight of the aqueous phase; and the non-aqueous phase comprises from... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070297997 - Personal care composition: Stable personal care composition comprising from about 1% to about 20% of a non-emulsifying silicone elastomer; from about 0.5% to about 10% of an emulsifying silicone elastomer; from about 5% to about 30% of an oil-soluble sunscreen; from about 1% to about 20% of a sunscreen solvent; and from about... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298004 - Conditioning composition comprising asymmetric dialkyl quaternized ammonium salt: Disclosed is a conditioning composition comprising: an asymmetric di-alkyl ammonium salt cationic surfactant; a high melting point fatty compound; and an aqueous carrier. The composition of the present invention can provide improved ease-to-rinse feel while maintaining conditioning benefits.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298005 - Injectable composition for treatment of skin defects or deformations: Provided are injectable compositions for correction of skin contour defects or deformations. Also provided are methods of use and manufacturing of compositions for correction of skin contour defects or deformations.... Agent: Wilson Sonsini Goodrich & Rosati

20070298007 - Slow release biocidal thermoplastic compositions and articles: In one aspect, the invention is directed to a biocidal composition, comprising a mixture of (a) a substantially oxidation-resistant thermoplastic polymer having a melting point of about 60° C. to about 100° C.; and (b) a composition for releasing chlorine dioxide gas upon exposure to moisture. In another aspect, the... Agent: D.a. Stauffer Patent Services LLC

20070298010 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.... Agent: Dla Piper US LLP

20070298013 - Animal nutritional supplement and method: The disclosed device relates to an animal nutritional supplement and more particularly to a method of using an animal nutritional supplement to reduce the incidence and effects of one or more chronic or acute conditions associated with nutritional deficiencies, gastrointestinal sand accumulation, colitis, inflammatory bowel disease, bacterial colitis, gastrointestinal pH... Agent: A Law Firm, P.C.

20070298018 - Novel lactobacillus bulgaricus strain and compositions: A novel strain of Lactobacillus delbrueckii, ssp. bulgaricus, including probiotic compositions comprising the bacteria, and methods for using the bacteria and/or the compositions for treatments of diseased states and boosting immune response.... Agent: Ice Miller LLP

20070298019 - Novel lactobacillus bulgaricus strain and compositions: A novel strain of Lactobacillus delbrueckii, ssp. bulgaricus, including probiotic compositions comprising the bacteria, and methods for using the bacteria and/or the compositions for treatments of diseased states and boosting immune response.... Agent: Ice Miller LLP

20070298023 - C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis: A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5... Agent: Kevin M. Farrell Pierce Atwood

20070298024 - C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis: Methods for reducing bleeding during fibrinolysis treatment and for inhibiting the enzymatic activity of a two-chain urokinase mutant are described. Exogenous C1-inactivator is administered during fibrinolysis treatment with the pro-urokinase mutant polypeptide, M5. The C1-inactivator inhibits the formation of two-chain M5 resulting in less hemostatic bleeding.... Agent: Kevin M. Farrell Pierce Atwood

20070297976 - Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific imaging: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a... Agent: Fulbright & Jaworski L.L.P.

20070297977 - Tumor necrosis factor-gamma: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection,... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070297978 - Method for radiolabeling antibodies with yttrium-90: Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070297979 - Pharmaceutical compounds: A pharmaceutical of the general formula Z-(L)n-V, wherein V denotes an amino acid sequence X1—X2-Val-Tyr-Ile-His-Pro-X8—X9—X10; L denotes a bond or a linker; Z denotes a group that optionally can carry an imaging moiety M; X1 denotes an amino acid; X2 denotes Arg or N-alkylated Arg or a mimetic of Arg... Agent: Ge Healthcare, Inc.

20070297980 - Geldanamycin and derivatives inhibit cancer invasion and identify novel targets: Geldanamycin derivatives that block the uPA-plasmin network and inhibit growth and invasion by glioblastoma cells and other tumors at femtomolar concentrations are potentially highly active anti-cancer drugs. GA and various 17-amino-17-demethoxygelddanamycin derivatives are disclosed that block HGF/SF-mediated Met tyrosine kinase receptor-dependent uPA activation at fM levels. Other ansamycins (macbecins I... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070297981 - Formulations and methods for treating dry eye: The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070297983 - Inhibition of breast carcinoma stem cell growth and metastasis: Disclosed is a method for inhibiting the growth of breast carcinoma stem cells. that express High Molecular Weight -Melanoma Associated Antigen (HMW-MAA). The method comprises administering to an individual a composition comprising an antibody reactive with HMW-MAA or a fragment of such an antibody in an amount effective to inhibit... Agent: Hodgson Russ LLP The Guaranty Building

20070297984 - Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses: The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a hypoxic cell. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a cell, increasing sensitivity of a tumor cell to radiation... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070297985 - Method and composition for enhancing bone formation: A method for screening for an osteogenic compound that is a PTEN antagonist. Also included are methods for enhancing bone formation and pharmaceutical compositions therefore, as well as methods for treating conditions associated with bone loss.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070297982 - Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use: The invention relates to Inter-alpha inhibitor proteins (IαIp). The invention further relates to processes for purification of IαIp compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20070297986 - Screening methods for identifying agents useful for treating or reducing visual impairment in mammals: Screening methods for identifying agents that affect vision in mammals are provided along with systems which may be used in such methods. Accordingly, methods of the present invention can be used for identifying agents that are useful for treating or reducing visual impairment as well as for identifying agents that... Agent: Lahive & Cockfield, LLP

20070297989 - Novel anti-inflammatory androstane derivatives: r

20070297992 - Product release system to atomize compositions containing hair-conditioning ingredients: A product release system to atomize cosmetic hair compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, and wherein the composition contains at least one hair-conditioning ingredient, which is selected from cationic surfactants, amino surfactants, silicone compounds, fatty alcohols, oils,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070297993 - Novel use of nonenolide: The present invention relates to the use of nonenolide for imparting, modifying and/or intensifying one or more smell or flavour impressions from the group consisting of hay, coumarin, lactone and richness in the mouth.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070297994 - Tooth whitening product: A tooth whitening product is provided. The tooth whitening product includes a film sized to cover the front surface of one or more teeth. The whitening composition contains a peroxide active with a concentration greater than about 7.5% by weight of the tooth whitening composition, and the tooth whitening composition... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298000 - High spf transparent or translucent naturally derived, cytoprotective, uv radiation resistant compositions: A composition comprising (a) at least one inorganic sun-block or sunscreen agent that is a proven non-endocrine disrupter, (b) at least one emollient or mixtures thereof proven to be a non-endocrine disrupter; (c) at least one emulsifier; and (d) an oil component capable of boosting SPF values. The compositions of... Agent: Guerry Leonard Grune

20070297999 - Kit containing an acidic composition and a composition based on a hydroxyalkyl urea: The present invention relates to a kit containing: a composition A containing a physiologically acceptable acidic medium and at least one skincare and/or scalp-care agent; a composition B, packaged separately from composition A, composition B containing a physiologically acceptable basic medium and at least one hydroxyalkyl urea of formula (I)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070297995 - Organo-mineral sunscreen composition adapted for being applied by a propulsion pump: The invention concerns a cosmetic or dermatological composition for protecting against ultraviolet rays based on a mixture consisting of a mineral screening agent and an organic screening agent having the generic chemical name (INN): methylene bis-benzotriazolyl tetramethylbutylphenol. The invention is characterized in that it exists in the form of a... Agent: Foley And Lardner LLP Suite 500

20070298001 - Self-tanning facial product having anti-wrinkle/anti-aging properties: A sunless facial self-tanning composition having anti-wrinkle/anti-aging properties. The composition contains safe effective amounts of sunless or self-tanning agents and peptides having anti-wrinkle/anti-aging properties.... Agent: Dunlap Codding & Rogers, P.C.

20070297998 - Surface-modified zinc-titanium mixed oxides: Surface-modified zinc-titanium mixed oxides are produced by treating zinc-titanium mixed oxides with a surface-modifying agent. They may be used for the production of sunscreen preparations.... Agent: Venable LLP

20070298002 - Decorative cosmetic product having a high water content: Decorative cosmetic product having a high water content The invention relates to a decorative cosmetic product having a high water content. The product comprises 70-92% by weight of water, 2.0-30% by weight of pigments, 2-8% by weight of a gel-forming agent with emulsifying properties comprising a mixture of sodium acrylate... Agent: Akerman Senterfitt

20070298003 - Hair treatment composition comprising sugar lactone: An aqueous hair treatment composition comprising: a) from 0.01% to 10% by weight of the total composition of beeswax; and b) from 0.01% to 10% by weight of the total composition of a sugar lactone.... Agent: Unilever Intellectual Property Group

20070298006 - Dendritic polymers with enhanced amplification and interior functionality: Dendritic polymers with enhanced amplification and interior functionality are disclosed. These dendritic polymers are made by use of fast, reactive ring-opening chemistry (or other fast reactions) combined with the use of branch cell reagents in a controlled way to rapidly and precisely build dendritic structures, generation by generation, with cleaner... Agent: Technology Law, PLLC

20070298008 - Method of bowel cleansing: Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution... Agent: Wilmerhale/boston

20070298009 - Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration: This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain,... Agent: Borson Law Group, PC

20070298011 - Use of parasitic biological agents for prevention and control of autoimmune diseases: The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response... Agent: Edwards Angell Palmer & Dodge LLP

20070298012 - Compositions and methods for tumor-targeted delivery of effector molecules: The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070298014 - Probiotic therapy of neonatal meningitis and method of using e. coli virulence determinants: Genes and proteins which modulate the virulence of meningitic E. coli bacteria, in particular neonatal meningitic strains of E. coli are provided. In particular, this invention provides sequences for the IbeA gene cluster (GimA) and the proteins encoded by these genes. Compositions and diagnostic assays utilizing the sequences are also... Agent: Raymond Yat Chan

20070298017 - Composition for treating baldness with stem cell derived from umbilical cord blood: Provided is a therapeutic technique for treating baldness, using an umbilical cord blood-derived stem cell. Transplantation of a composition for treating baldness into a bald area of a patient can make great contributions to treatment for baldness, wherein the composition comprises stem cells isolated and cultured from umbilical cord blood... Agent: Venable LLP

20070298016 - Methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hbs): The present invention relates to methods for obtaining endodermal progenitor cells and further differentiating these to hepatocyte-like cells. Knowledge about the cell composition prior to the initiation of terminal differentiation is used to select one of two different protocols and one of two type of intermediate progenitors depending on the... Agent: Buchanan, Ingersoll & Rooney PC

20070298015 - Treatment of muscular dystrophy with mobilized peripheral blood pluripotent cells: The invention features methods for treating a patient suffering from muscular dystrophy by administering mobilized pluripotent cells isolated from peripheral blood.... Agent: Clark & Elbing LLP

20070298020 - Apoptotic entities for use in treatment of endothelium dysfunction disorders: Treatment and/or prophylaxis of endothelial dysfunction-related disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells.... Agent: Foley & Lardner LLP

20070298022 - Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action: A peptide of phospholipase A2 had been detected in human plasma and synthesised. The peptide was injected into mice and gene expression profiling on many organs performed. Phospholipase A2 showed significant effects on regulation of gene expression in the liver. The genes affected are members of the integrin signalling pathway,... Agent: Novartis Corporate Intellectual Property

20070298021 - Methods and compositions for the treatment or prevention of secondary ischemic injury: After a primary ischemic injury, which predominantly results in necrosis, there is a secondary injury in the neighbouring tissue, due at least to some extent to apoptosis. This secondary damage is usually not evident until several days after the initial ischemic event. The present invention provides methods of preventing, treating... Agent: Dla Piper US LLP

20070298025 - Pharmaceutical compositions and methods for reducing body fat: The invention concerns a method of reducing body fat content of a subject in need thereof, the method comprising administering to the subject an agent capable of down-regulating activity and/or expression of at least one component participating in protein digestion and/or absorption. Such agents may be (i) an oligonucleotide directed... Agent: Merchant & Gould PC

20070298030 - Copper lowering treatment of inflammatory and fibrotic diseases: The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention... Agent: Casimir Jones, S.c.

20070298028 - Diagnostics and therapeutics for diseases associated with kallikrein 3 (klk3): The invention provides a human KLK3 which is associated with the endocrine system and hormone disorders, cardiovascular disorders, metabolic diseases, cancer disorders, neurological disorders, urological disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrine system and hormone... Agent: Banner & Witcoff, Ltd.

20070298026 - Methods for identifying treatment and inducing infertility using smc1-beta: The present invention is directed to methods and compositions for use in the diagnosis and treatment of reproductive fertility. More particularly, it is directed to methods and compositions that can be used in male and female contraception and fertility.... Agent: Marshall, Gerstein & Borun LLP

20070298031 - Methods for preventing or treating neuromuscular or muscular conditions by peripherally administered erythropoietin: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral... Agent: Jones Day

20070298027 - Novel target for antiderpressant therapy: The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070298029 - Treatment of neurodegenerative diseases by the use of degs inhibitors: The present invention relates to the use of DEGS interacting molecules, especially DEGS inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, particularly Alzheimer's disease.... Agent: Clark & Elbing LLP

20070298033 - Human anti-idiotypic antibody fragments that mimic her-2/neu: This invention relates to human anti-idiotypic antibody fragments, especially scFv, characterized by the ability to mimic Her-2/neu tumor associated antigen. These antibody fragments are promising candidates for active immunotherapy for cancer patients positive for Her-2/neu.... Agent: Stites & Harbison PLLC

20070298032 - Proteins involved in quorum sensing: The invention relates to a method of regulating quorum sensing in bacteria by modulating the activation of LuxR or a homologue thereof. Such modulation generally occurs when the bacteria are in the pre-quorate or quorate stage and may be achieved by targeting antibodies to LuxR or a homologue thereof.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070298036 - Pro71238 polypeptides: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20070298035 - Reducing imunogenicities of immunoglobulins by framework-patching: Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3 and FR4),... Agent: Rossi, Kimms & Mcdowell LLP.

20070298034 - Sulfotyrosine specific antibodies and uses therefor: This application relates to sulfotyrosine specific antibodies that are capable of binding selectively to sulfated tyrosine (sulfotyrosine), as well as their production and use. In certain embodiments, the antibodies distinguish sulfated tyrosine containing proteins from phosphorylated tyrosine containing proteins. Methods to detect or quantitate the presence of sulfotyrosine and/or sulfotyrosine... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070298037 - Ztnfr14, a tumor necrosis factor receptor: Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070298038 - Compositions and methods for treating kidney disease: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070298039 - Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of o the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have... Agent: Fish & Richardson P.C.

20070298040 - Methods of treating seronegative arthropathy with anti-tnf antibodies: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFαx-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070298041 - Ligands that enhance endogenous compounds: The invention relates to ligands that comprise a moiety (e.g., a dAb) that has a binding site with binding specificity for an endogenous target compound but do not substantially inhibit the activity of said endogenous target compound. Preferably, the ligand does not bind to the active site of an endogenous... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070298042 - Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein: In this application are described Ebola GP monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the... Agent: Elizabeth Arwine U.s. Army Medical Research And Materiel Command

20070298043 - Novel antibacterial agents and methods of identifying and utilizing same: A method of identifying a molecule capable of inducing death of a bacterial cell which includes exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules, and identifying a molecule of the plurality of molecules capable of preventing or disrupting binding... Agent: Martin D. Moyniham Prtsi, Inc.

20070298044 - Enhancing the efficacy of immunotherapies by supplementing with complement: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.... Agent: Barnes & Thornburg LLP

20070298045 - Method and vaccine for non-genetically engineered atavism growth enhancement: A method and vaccine for non-genetically engineered atavism growth enhancement, which injects the vaccine with myostatin antibody containing muscular tissues into the vertebrate mother's body prior to the pregnancy stage; the genes of myostatin that contain muscular tissues can enhance the muscular mass and growth rate of the muscle.... Agent: Genereach Biotechnology Corporation

20070298046 - Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070298047 - Recombinant antigens for diagnosis and prevention of murine typhus: The invention relates to the construction of recombinant, immunodominant Rickettsia typhi proteins. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays. The proteins can also be used in anti-Rickettsia typhi immunogenic formulations.... Agent: Naval Medical Research Center Attn: (code 00l)

20070298048 - Non-viral gene delivery system: The present invention concerns a composition comprising complexes of cationic chitosan oligomers derived from the cationic polysaccharide chitosan, wherein said cationic oligomers contain a weight fraction of less than 20% of oligomers with a Degree of Polymerization (DP)<10 in addition to a weight fraction of less than 20% with DP>50,... Agent: Connolly Bove Lodge & Hutz, LLP

20070298049 - Therapeutic agent for polycystic ovary syndrome (pcos): The present invention provides a therapeutic agent for treating polycystic ovary syndrome (PCOS), which exhibits few, if any, side effects, is effective at inducing ovulation, and is safely available for not only females who desire to bear children, but also for unmarried or young females. A therapeutic agent for polycystic... Agent: Wood, Herron & Evans, LLP

20070298050 - Robust expression of a bioactive mammalian protein in chlamydomonas chloroplast: Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of combinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble... Agent: Dla Piper US LLP

20070298051 - Adjuvants of immune response: The present invention features methods to substantially increase the immunogenicity of a vaccine, preferably a DNA vaccine, and involves providing a mammal with a vaccine regimen, which includes an immunogen and Flt3L in combination with MIP-1α or MIP-3α. The methods of the present invention can be used for the prevention... Agent: Clark & Elbing LLP

20070298052 - Drying process for presserving an active agent as a higly viscous liquid: The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilising agent, subjecting the preservation... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070298053 - Cattle reproductive disease vaccines: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira... Agent: Peter I. Bernstein, Scully, Scott, Murphy & Presser

20070298054 - Highly safe smallpox vaccine virus and vaccinia virus vector: Objects of the present invention are to generate vaccine strains that undergo reversion (atavism) with difficulty and to provide smallpox vaccines with higher safety. The vaccine viruses are deficient in a part or the whole of the B5R gene of a vaccinia viral strain, LC16m8 or LC16mO, and produce no... Agent: Birch Stewart Kolasch & Birch

20070298055 - Polypeptide: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use... Agent: Townsend And Townsend And Crew, LLP

20070298057 - Composition and method for modulating addictive behaviors: Improved compositions and methods useful in the treatment and prevention of impulsive, compulsive, reward seeking, and other addictive behaviors, including applications involving the behavioral/cognitive process of assigning importance, maintaining attention, and assessing salience. The composition includes Vitex agnus-castus (Chastetree berry) extract in an effective amount for supporting and promoting a... Agent: Patton Boggs LLP

20070298056 - Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter... Agent: Foley And Lardner LLP Suite 500

20070298058 - Pharmaceutical compositions comprising ascomycin: The invention relates to pharmaceutical compositions comprising an ascomycin in dissolved form and a pharmaceutically acceptable cellulose derivative for prevention or reduction of crystal growth.... Agent: Novartis Corporate Intellectual Property

20070298059 - Method for identification and verification of products containing titanium dioxide pigment particles: A method for marking titanium dioxide pigment particles, as well as a method for identifying and verifying products via the marked titanium dioxide pigment particles contained in these products. The marker substance(s) is/are added during titanium dioxide production, preferably during surface treatment, drying or steam-milling. Particularly suitable as marker substances... Agent: Locke Lord Bissell & Liddell LLP

20070298060 - Method for depletion of caries-causing bacteria in the oral cavity: Herein is provided a method for treating or preventing caries by applying a caries-causing agent removal device, a device capable of selectively and preferentially binding the caries-causing agent compare with other surrounding non-cariogenic organisms. There is also provided a set of compounds for formulating the device thereof. Exemplary compounds include... Agent: Hogan & Hartson L.L.P.

20070298061 - Process for manufacturing a delivery system for active components as part of an edible compostion: A method of manufacturing a delivery system of at least one active component encapsulated in an encapsulating material, which is useful, for example, for providing delayed and/or controlled release of the active is described.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070298062 - Resin powder for dermatologic composition, skin cleansing agent and cosmetic composition using the powder, and preparation processes of the powder: Provided is a resin powder for a dermatologic composition composed of resin particles having an average volume particle size of 2.0 to 20.0 μm, a shape factor SF1 of 110 to 140 and an average volume particle size distribution GSDv of 1.3 or less. Also disclosed are a skin cleansing... Agent: Oliff & Berridge, PLC

20070298063 - Equine gnat repellant: An gnat repellant is provided from one or more active ingredients in a oil base, that is safe and effective over long periods on herd animals and articles worn by animals. A method for repelling gnat in herd animals and treating gnat bites on herd animals is also included.... Agent: Ratnerprestia

20070298064 - Structures that inhibit microbial growth: Structures treated with a microbiological interception enhancing agent comprising of a water-soluble cationic material having a counter ion associated therewith at specific sites on the cationic material, in combination with a biologically active metal salt, wherein the counter ion associated with the cationic material preferentially precipitates with at least a... Agent: Law Office Of Delio & Peterson, LLC.

20070298066 - Biodegradable linkers for molecular therapies: A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate... Agent: Ratnerprestia

20070298065 - Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and the compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds... Agent: Vertex Pharmaceuticals Inc.

20070298067 - Control release drug coating for medical devices: A medical device having multiple layers of a drug-loaded coating. At least one of the layers is more hydrophilic than at least another one of the layers. Also provided is a method for controlling the drug release profile from a coated medical device using multiple layers of modified and/or unmodified... Agent: Kenyon & Kenyon LLP

20070298068 - Intraocular implants and methods and kits therefor: Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within Schlemm's canal and maintains the patency of the canal without substantially interfering with transmural fluid flow across the canal. The devices utilize the natural drainage process of the eye and can... Agent: Morrison & Foerster LLP

20070298069 - Medical devices for release of low solubility therapeutic agents: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric carrier regions. These polymeric carrier regions, in turn, contain a polymer, a low solubility therapeutic agent, and a solubilizing agent.... Agent: Mayer & Williams PC

20070298071 - Bioactive scaffold for therapeutic and adhesion prevention applications: A device for inhibiting adhesion of apposing human body tissue layers includes a scaffold having a designated mean pore size, relative density, and degradation half-life. The scaffold may be operably positioned between apposing tissue layers, such as proximate adhesiogenic layers at a wound site, so as to permit remesothelialization of... Agent: Mark J. Burns Haugen Law Firm Pllp

20070298072 - Cylindrical body and manufacturing method thereof: It is an object of the present invention to provide a cylindrical body which has an excellent elastic modulus and elastic recovery and is suitable for use as a scaffold material for revascularization. It is a further object of the present invention to provide a cylindrical body which has an... Agent: Sughrue Mion, PLLC

20070298070 - Nerve regeneration employing keratin biomaterials: A keratin hydrogel matrix serves as an effective acellular scaffold for axonal regeneration and facilitates functional nerve recovery.... Agent: Myers Bigel Sibley & Sajovec

20070298073 - Steroid-containing sustained release intraocular implants and related methods: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although... Agent: Stout, Uxa, Buyan & Mullins LLP

20070298074 - Steroid-containing sustained release intraocular implants and related methods: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although... Agent: Stephen Donovan Allergan, Inc.

20070298076 - Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Stephen Donovan Allergan, Inc.

20070298075 - Punctal plugs for the delivery of active agents: The invention provides punctal plugs for the delivery of active agent to one or both of the tear fluid of the eye and to the nasolacrimal duct. The plugs of the invention have a body, a reservoir contained within the body, and optionally a collarette. The reservoir has at least... Agent: Philip S. Johnson Johnson & Johnson

20070298077 - Consumable veterinary medicine delivery device: A medicine delivery device for oral administration of a medication, the device comprising an edible outer shell including a container piece comprised of a wall bounded by an outer surface, an inner surface, and a mating surface, and a recessed cavity formed within the inner surface; and a cap piece... Agent: John M. Hammond Patent Innovations LLC

20070298079 - Food fortified with omega-3 fatty acids: A food product is provided which is fortified with omega-3 fatty acids. The omega-3 fatty acids include docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The omega-3 fatty acids are added to the food product in a desired amount and blended sufficiently by mixing.... Agent: Banner & Witcoff, Ltd. And Attorneys For Client No. 006943

20070298078 - Water soluble article for imparting dietary fiber to bottled water: We disclose a tablet containing at least one water-soluble fiber source, wherein the tablet is of a size and shape susceptible to insertion into a package of a beverage and the tablet will dissolve in the beverage in the absence of agitation in less than about 2 minutes. We also... Agent: Williams, Morgan & Amerson

20070298083 - Concentrated omega-3 fatty acids and mixtures containing them: A stable aqueous emulsion comprising water, a blend of esters including esters of polyunsaturated fatty acids, such as omega-3 fatty acids, emulsifiers and stabilizers is disclosed. The emulsion may be used as a beverage or as an additive that may be added to a beverage or a food product. The... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298082 - Method and devices for forming articles: The present invention is predicated upon methods and devices for forming numerous articles for various applications including nutritional applications, medicinal applications, or other useful applications for plants, animals or otherwise. In one aspect, the present invention provides methods and devices for forming high quality pellets using alginates as a retention... Agent: Dobrusin & Thennisch PC

20070298081 - Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy: The invention relates to the food and medical industries, medical cosmetics, dermatology, agriculture and the mixed feed industry. According to the invention vicinal dithioglycole (common formula RCH(SH)CH(SH)R−1 (I)) is used as a food additive, a food product, physiologically-active substances and active ingredients of forage additives and of forage, in cosmetic... Agent: Ladas & Parry

20070298080 - Strain of lactobacillus acidophilus having analgesic properties in the gastrointestinal system: The invention proposes the use of at least one strain of Lactobacillus acidophilus to prepare a support administered to humans or animals with an analgesic purpose in the gastrointestinal system.... Agent: Marshall, Gerstein & Borun LLP

20070298084 - Flat system for using in the oral cavity: The invention relates to a flat system for using in the oral cavity, and to a method for the production thereof. Said system consists of at least one upper water-soluble covering layer and at least one lower water-soluble covering layer. At least one intermediate layer is provided between the upper... Agent: Striker Striker & Stenby

20070298085 - Skin sanitizing object: The present invention provides a novel method of sanitizing skin surfaces, preferably the hands. The sanitizing object is a moldable and pliable composition with at least one regenerable surface and an antimicrobial agent incorporated therein. The antimicrobial agent is capable of transfer from the object to a skin surface. The... Agent: The Clorox Company

20070298086 - Tussi bag: e

20070298087 - Two-phase mucoadhesive composition: A novel two-phase, film-forming, mucoadhesive gel composition has been developed. The composition contains an anhydrous non-aqueous solvent, a water-insoluble polymer that is dissolved in the non-aqueous solvent, and a water-soluble polymer that is dispersed in the non-aqueous solvent. The composition adheres to water-bearing surfaces, such as to moistened skin or... Agent: Howard Eisenberg, Esq.

20070298088 - Tooth whitening products: A tooth whitening product is provided. The tooth whitening product includes a barrier layer sized to cover the front surface of one or more teeth. The whitening composition contains a peroxide active with a concentration greater than about 7.5% by weight of the tooth whitening composition, and the tooth whitening... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298089 - Drug for external use and adhesive patch: An external preparation characterized by containing a pharmacologically active component such as an anti-inflammatory drug, and a lipophilic polyglycerin fatty acid ester.... Agent: Nath & Associates

20070298090 - Intraoral delivery of nicotine for smoking cessation: Dosage forms of a nicotine delivery system are disclosed in which a mucoadhesive film, made up of one or more non-microbial hydrocolloid(s) and an effective dose of nicotine, dissolves when applied intraorally to release the nicotine which is absorbed through the oramucosac and directly reaches systemic circulation. Methods for preparing... Agent: Lucas & Mercanti, LLP

20070298091 - Transdermal therapeutic system for administering analgesics: Transdermal therapeutic systems for administering analgesics, preferably buprenorphine or one of its pharmaceutically acceptable salts or pro-drugs, and processes for the production of such systems.... Agent: Crowell & Moring LLP Intellectual Property Group

20070298092 - Compositions for delivery of drug combinations: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.... Agent: Morrison & Foerster LLP

20070298094 - Medicinal composition, preparation and combined preparation: A medicinal composition and a medicinal preparation which are capable of inhibiting complement activation. The medicinal composition comprises: a medicinal preparation modified with a first hydrophilic polymer; and a second hydrophilic polymer. The medicinal preparation contains as an active ingredient a second hydrophilic polymer which inhibits an immunoreaction caused by... Agent: Buchanan, Ingersoll & Rooney PC

20070298093 - Synergistic liposomal adjuvants: The present invention relates to liposome, mixtures or liposomes and liposomal compositions comprising at least two different adjuvants and a therapeutic agent, their production and use for the prevention and therapy of proliferative diseases, infectious diseases, vascular diseases, rheumatoid diseases, inflammatory diseases, immune diseases, in particular autoimmune diseases and allergies.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070298096 - Analgesic/antipyretic compositions for enhanced absorption: The onset of activity of a first analgesic/antipyretic composition containing an analgesic/antipyretic effective amount of acetaminophen, caffeine and, optionally, aspirin is shortened by incorporating in the first composition an onset of analgesic/antipyretic activity shortening amount of at least one alkaline agent whereby a second composition is produced. The second composition... Agent: Novartis Corporate Intellectual Property

20070298097 - Multi-carotenoids compositions and uses therefor: A stable nutritional supplement composition for oral administration comprising about 71% by weight, of a tomato extract containing therein at least 2% to 10% by weight of lycopene, 0.25% to 2% by weight of phytoene, and 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a... Agent: Fasken Martineau Dumoulin, LLP

20070298095 - Surface-modified and solubility-improved hard capsule: A hard capsule comprising a water-soluble cellulose derivative as a base material, characterized in that the water-soluble cellulose derivative is formulated with one or two or more compound(s) selected from polyvinylpyrrolidones, copolymers of vinylpyrrolidone with vinyl acetate, and polyethylene glycols having a weight-average molecular weight of 400 to 100,000. The... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070298098 - Controlled release compositions comprising levetiracetam: The invention relates to a controlled release composition comprising levetiracetam for the treatment of epilepsy. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of levetiracetam and the modified release component or formulation preferably comprises... Agent: Synnestvedt & Lechner LLP

20070298099 - Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide: N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2)... Agent: Merck And Co., Inc

20070298100 - Compressed pharmaceutical compositions comprising peg and electrolytes: The invention provides a compressed pharmaceutical composition comprising polyethylene glycol of molecular weight from 2000 to 4500, wherein the polyethylene glycol makes up from 80 to 99.5% by weight of the composition, one or more electrolytes for the treatment of constipation, faecal impaction, faecal retention, intestinal gas and cramping, or... Agent: Leon R Yankwich Yankwich & Associates

20070298101 - Controlled-release formulation comprising tamsulosin hydrochloride: Taught herein is a solid, oral, controlled-release pharmaceutical composition of tamsulosin hydrochloride in the form of an enteric-coated tablet, wherein tamsulosin hydrochloride is homogenously dispersed within a matrix consisting of a mixture of a fatty component and a hydrophilic component, together with at least one diluent, and optionally other pharmaceutically... Agent: Matthias Scholl

20070298102 - Extended release pharmaceutical composition of celecoxib: The invention concerns new pharmaceutical agents comprising the known medicinal celecoxib for oral administration and adapted to release the celecoxib in a controlled manner over an extended period, typically for a period of up 10-12 hours or more. The invention also includes a method for the production of the new... Agent: Buchanan, Ingersoll & Rooney PC

20070298104 - Cyanoisoquinoline compounds and methods of use thereof: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:... Agent: Foley & Lardner LLP

20070298105 - Methods of treating conditions by sustained release administration of benzimidazole derivatives: Disclosed are methods including orally administering oral sustained release dosage forms comprising a benzimidazole derivative to a patient suffering from one or more gastric acid related diseases; wherein the benzimidazole derivative is sustainably released from the oral sustained release dosage form for a period of at least about 10 hours,... Agent: Philip S. Johnson Johnson & Johnson

20070298103 - Particulates: A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are preferably made by melt extrusion, and can have rubbery characteristics and can exhibit tamper resistance.... Agent: Duane Morris LLP Patent Department

20070298106 - Sustained release formulation containing selective serotonin reuptake inhibitor and method for the preparation thereof: A sustained release formulation of a selective serotonin reuptake inhibitor (SSRI), comprising the SSRI as an active ingredient; a matrix comprising a water-soluble and erodible polymer, a hydrogel for shape sustenance and a pharmaceutically acceptable additive, the SSRI being embedded in the matrix, is capable of maintaining a constant drug... Agent: Sughrue Mion, PLLC

20070298107 - Pharmaceutical compositions of mirtazapine: The present invention relates to pharmaceutical compositions of mirtazapine or its pharmaceutically acceptable salts. More particularly, the present invention relates to solid unit dosage forms of anhydrous mirtazapine or its pharmaceutically acceptable salts suitable for oral administration. The present invention also relates to a process for the preparation of pharmaceutical... Agent: Jay Akhave

20070298108 - Pharmaceutical formulation: Composition were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcrystalline cellulose, magnesium oxide and polyethylene glycol.... Agent: Novartis Corporate Intellectual Property

20070298110 - Methods for embedding nanoparticles: Method for producing nanoparticles that can be used in a variety of applications, including improving performance of electrostatographic apparatuses. More particularly, a method for producing nanoparticles through a precipitation process occurring in a matrix of two or more molecules in a multi-solvent system.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070298112 - Crystalline forms of a biphenyl compound: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and... Agent: Theravance, Inc.

20070298111 - Fine particle-containing composition and manufacturing method therefor: The present invention provides a composition containing fine particles of a hardly-soluble drug which is stable and is not affected by storage environment conditions, as well as a manufacturing method therefor. The present invention provides a fine particle-containing composition containing fine particles of the hardly-soluble drug, a surfactant and a... Agent: Birch Stewart Kolasch & Birch

20070298109 - Nano-scale devices: Nano-scale devices with filter zones that define the size of the resulting nanoparticles. The filter zones may have nanotubes with diameters that are the maximum dimension of the resulting particles or the filter zones may have filtering particles arranged in a predetermined array with interstices defining the maximum dimension of... Agent: Woodcock Washburn LLP

20070298114 - High glass transition temperature absorbable microspheres: Absorbable microspheres comprising a copolymer formed from greater than 80 to about 99 mole percent D,L-lactide, L(−)-lactide, D(+)-lactide, or meso-lactide and combinations thereof, and about 1 to less than 20 mole percent of a different second monomer selected from the group consisting of p-dioxanone and trimethylene carbonate and combinations thereof,... Agent: Philip S. Johnson Johnson & Johnson

20070298113 - Semi-crystalline absorbable microspheres: The present invention is directed to absorbable microspheres comprising a copolymer formed from greater than 88 to about 99 mole percent ε-caprolactone or p-dioxanone, and about 1 to less than 12 mole percent of a different second monomer selected from the group consisting of glycolide, p-dioxanone, trimethylene carbonate and the... Agent: Philip S. Johnson Johnson & Johnson

20070298115 - Nanoparticulate fibrate formulations: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070298116 - Amorphous, spray-dried powders having a reduced moisture content and a high long term stability: The present invention relates to spray-dried amorphous powders which contain a pharmaceutical active substance and a matrix-forming agent, preferably a polymer, sugar or sugar alcohol in an amount of ≧20-60% (w/w). The powders have a moisture content which is less than 1.2% (w/w), preferably less than 1% (w/w). The present... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070298117 - Compositions and kits comprising a melatonin component and a chondroprotective component: Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, a chondroprotective component, or both, and wherein each kit comprises a melatonin component and a chondroprotective component. The compositions and kits are useful for restorative sleep function and restorative joint structure or restorative joint function. Further disclosed... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298118 - Exosome transfer of nucleic acids to cells: Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.... Agent: Lynn E Barber

20070298119 - Strontium-apatite cement preparations, cements formed therefrom, and uses thereof: Calcium-strontium-hydroxyphosphate (strontium-apatite-) cement preparations are described, comprising a powder mixture, which contains molar quantities of the components calcium (Ca), strontium (Sr) and phosphate (P) in the mixture in the ranges 1.00<Ca/P≦1.50 and 0<Sr/P<1.5, together with an alkali salt or an ammonium salt of phosphoric acid, and with water and/or an... Agent: Townsend And Townsend And Crew, LLP

20070298120 - Photoreactive compound specifically binding to calcium binding proteins: The present invention provides a photoreactive reagent that binds specifically to Ca2+-binding proteins, links to them covalently after photo-activation, and labels them. The novel reagent enables the characterization, purification, inhibition and screening of Ca2+-binding proteins, as well as the preparation of a new affinity chromatography matrix and a new protein... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber

20070298121 - Treatment of wounds and compositions employed: A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.... Agent: O'melveny & Myers LLP

20070298123 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070298122 - Copper lowering treatment of inflammatory and fibrotic diseases: The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention... Agent: Medlen & Carroll, LLP

20070298124 - Use of tellurium compounds for inhibiton of interleukin-converting enzyme: Use of tellurium-containing compounds for treating conditions in which inhibition of caspase-1/interleuFkin-1β enzyme (ICE) is beneficial is disclosed.... Agent: Martin D Moynihan Prtsi Inc

20070298125 - Medical solution, a method for producing said medical solution and use thereof: The present invention relates to a medical solution, a method for producing said medical solution, a multi-compartment bag containing the medical solution as well as use of said medical solution. According to the invention the medical solution comprises a first single solution comprising bicarbonate and carbonate in such proportions that... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070298126 - Method for the eradication of pathogens including s. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells: A method for killing or substantially eradicating a pathogen in the upper respiratory tract of a mammal is disclosed. The method comprises generating molecular iodine (I2) in situ using an oxidant-reductant reaction with a minimum concentration of at least about 25 ppm of I2 and I2 comprises at least 40%... Agent: Anderson Kill & Olick, P.C.

20070298127 - Diazene-bridged crown ether lithium compounds and methods for their use: This invention provides a method for treating an eye disease in a patient comprising: providing a photosensitive prodrug that releases upon exposure to light an active ingredient to treat the eye disease; administering the prodrug in a pharmaceutically accepted vehicle to the subject, and exposing the eye of the subject... Agent: Cooper & Dunham, LLP

20070298128 - Antibacterial zeolite particles and antibacterial resin composition: The present invention herein provides antibacterial zeolite particles whose ion-exchangeable ions have completely or partially been replaced with silver ions and zinc ions, wherein the ratio (A/B) of the silver ion concentration (A) to the zinc ion concentration (B) in the antibacterial zeolite particles increases in the direction along the... Agent: Nixon & Vanderhye, PC

20070298129 - Compounds and compositions for treating neuronal death or neurological dysfunction: The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration... Agent: Seed Intellectual Property Law Group PLLC

20070298132 - Berberine as a selective lung cancer agent: Berberine or its salts or derivatives are identified as the active compound for selectively inhibiting lung cancer, potentially without toxic side effects. Berberine is preferably obtained by synthesis or partial synthesis, or is obtained from natural sources, such as Coptis teeta, or other berberine containing plants. Berberine and its derivatives... Agent: Adams Law Office

20070298130 - Convolvulus soldanella compositions and methods of use: Compositions and methods for treating patients suffering from a disorder characterized by an increased angiogenesis, an inflammatory skin disease, and/or to effect weight loss or treat obesity are described. Included are compositions comprised of an extract of sea bindweed (Convolvulus soldanella).... Agent: Perkins Coie LLP

20070298131 - Synergistic and residual pesticidal compositions containing plant essential oils: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal... Agent: Nixon & Vanderhye, PC

20070298133 - Compositions and kits comprising a melatonin component and a flavanol component: Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, a flavanol component, or both, and wherein each kit comprises a melatonin component and a flavanol component. The compositions and kits are useful for restorative sleep function and enhanced energy. Further disclosed herein are methods of using... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070298134 - Composition and method for scalp and hair treatment: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness,... Agent: Sughrue Mion, PLLC

20070298135 - Topical herbal formulations: An herbal formulation is described as an effective treatment of burn injuries and chronic wounds. The herbal formulation comprises an extract of Paris and Sanguisorba prepared by infusing Paris and Sanguisorba in a liquid medium having a boiling point of no more than 160° C.... Agent: Seed Intellectual Property Law Group PLLC

20070298136 - Cholesterol regulating agent: It is an object of the present invention to provide a HDL cholesterol-raising agent which can selectively raise or maintain HDL cholesterol level, an LDL cholesterol-lowering agent which can selectively lower LDL cholesterol level, a composition which can selectively raise of maintain HDL cholesterol level, a method for raising or... Agent: John L. Cordani, Esq. Carmody & Torrance, LLP

20070292344 - Children's first aid kit for cuts and scrapes: The present disclosure provides a children's first aid kit suitable for treating minor scrapes and cuts. The compact kit is integral with a reusable cooling mechanism designed to provide a cooling sensation to the injured area. The kit is further integral with a supply of antiseptic medicine and bandages, and... Agent: West & Associates, A PC

20070292360 - Process and composition for oral hygiene: A composition for oral hygiene which is anti-plaque and treats gingivitis. The composition contains a monobasic iodide salt to provide at least 30 ppm of available iodine. The composition includes an oxidizing agent, an organic acid and a buffer. There is also provided a method of treating gingivitis and the... Agent: John Lezdey & Associates

20070292373 - Self tanning or sunscreen cosmetic compositions: A self-tanning or sunscreen cosmetic composition comprising a first resting color and a second application color comprising a water phase, and oil phase, and diffusive pigments suspended in the oil phase, wherein the diffusive pigments suspended in the oil phase provide the first resting color and upon diffusion out of... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070292375 - Piperidinium compounds and cosmetic compositions containing them: Cosmetic or dermatological compositions which comprise at least one piperidinium salt, preferably a 4-[(2-cyclopentyl-2-hydroxyphenylacetyl)oxy]-1,1-dimethyl-piperidinium salt, and the use thereof, particularly as antiperspirants. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20070292380 - Hair conditioning composition containing a non-guar galactomannan polymer derivative: s

20070292382 - Skin care compositions: Provided are compositions which are suitable for topical application to human skin for cleansing and anti-microbial properties. In one preferred embodiment, the compositions include a glyceryl monoazelate ester. In another embodiment, the compositions include a glyceryl monoazelate monolaurate ester. It is postulated that bacteria on the skin cleave the ester... Agent: Christopher J. Whewell Western Patent Group

20070292392 - Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma: It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.... Agent: Lucas & Mercanti, LLP

20070292393 - Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma: It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.... Agent: Lucas & Mercanti, LLP

20070292401 - Soft tissue repair and regeneration using stem cell products: Stem cells products having the potential to support cells of a soft tissue lineage, and methods of preparation and use of those stem cell products are disclosed. The invention also relates to methods for the use of such stem cells products in the regeneration and repair of soft tissue, and... Agent: Philip S. Johnson Johnson & Johnson

20070292398 - Differentiation of multi-lineage progenitor cells to hepatocytes: Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into mature hepatocytes.... Agent: Fish & Richardson P.C.

20070292346 - Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk: This invention relates to a method for assessing risk of lung and/or breast cancer. Specifically, in one embodiment it relates to utilizing Lng105 to determine the risk of lung cancer. Specific antibodies are disclosed.... Agent: Licata & Tyrrell P.C.

20070292345 - Method and materials for use in diagnosing viral myocarditis: The invention consists of assay methods, assay kits and antibodies for detecting the polypeptide fragments of dystrophin protein cleavage by enteroviral protease 2A as a result of an enteroviral infection in the heart. The presence of dystrophin cleavage products in the myocytes or blood of a subject is diagnostic for... Agent: Foley & Lardner LLP

20070292347 - Peptides associated with hla-dr mhc clas ii molecules involved in autoimmune diseases: Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with Rheumatoid arthritis. These novel peptides provide the basis for new methods of diagnosis and... Agent: Sim & Mcburney

20070292348 - Low-density lipoprotein receptor 6 (lrp6) as a mammary stem cell marker and related methods: A method for enriching a population of somatic mammary stem cells or mammary tumor stem cells based on low-density lipoprotein receptor-related protein 6 (LRP6). Also included are methods for screening for LRP6 modulators, as well as methods for reducing Wnt signaling, for treating Wnt signaling-related diseases, for detecting mammary basal-like... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070292351 - Assay for efficacy of histone deacetylase inhibitors: The invention provides methods for assessing the efficacy of histone deacetylase inhibitors using biomarkers which can be used in human clinical trials and which are more quantitative, easy to be used and more relevant to clinical outcome for PD monitoring than existing assays. The method according to the invention utilizes... Agent: Keown & Zucchero, LLP

20070292349 - Itpks as modifiers of the igfr pathway and methods of use: Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070292350 - Method for testing a compound for a therapeutic effect and a diagnostic method: A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. The compound may be used for treating disorders related to unbalanced... Agent: Young & Thompson

20070292354 - Contrast agents encapsulating systems for cest imaging: The present invention concerns a contrast agent compound for CEST imaging wherein said contrast agent comprises a proton pool encapsulating system that contains a pool of water mobile shifted protons.... Agent: Birch Stewart Kolasch & Birch

20070292353 - Nanoparticles comprising an intracellular targeting element and preparation and use thereof: The present invention relates to novel activatable particles which can be used in the health field. More specifically, the invention relates to composite particles comprising an intracellular targeting element, which can generate a response when excited, and to the uses thereof in the health field, particularly in relation to human... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070292352 - Methods and compositions for diagnostic and therapeutic targeting of cox-2: The presently disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also provided are methods for using the disclosed compositions for diagnosing (i.e., by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activity.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070292355 - Anti-infection augmentation foamable compositions and kit and uses thereof: Anti-infective foamable composition and kits include a foamable carrier; a therapeutically safe and effective concentration of an anti-infective agent; an augmenting agent selected from the group consisting of a keratolytic agent and a skin penetration enhancer; and a propellant. The composition is housed in a container and upon release is... Agent: Wilmerhale/boston

20070292356 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20070292357 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20070292359 - Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof: The present invention teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent water and a liquefied hydrocarbon gas propellant; and pharmaceutical compositions thereof. The present invention further teaches a foamable pharmaceutical carrier comprising polypropylene glycol (PPG) alkyl ether, a surface-active agent, and a liquefied hydrocarbon... Agent: Wilmerhale/boston

20070292358 - Storage-stable emulsion spray product: A perspiration-inhibiting and/or deodorizing cosmetic product that encompasses a water-in-oil emulsion having at least one antiperspirant and/or deodorant active substance, at least one propellant, and an aerosol dispensing apparatus, the parts of the valve of the dispensing apparatus that come into contact with the emulsion being made of nonmetallic materials.... Agent: Paul & Paul

20070292361 - Encapsulation compositions: Microcapsules having hydrogel walls and a content, the content including a flavour or fragrance active and a solvent therefor, the solvent having a Clog P>5, the solvent being present in such a proportion that the active in solution has a calculated base-ten logarithm of the partition coefficient between the solvent... Agent: Curatolo Sidoti Co., Lpa

20070292367 - Method and system for facilitating and maintaining oral health through prescribed applications of oral compositions: A system and method for facilitating and maintaining oral health care through regular applications of oral compositions are provided. An exemplary system for facilitating oral health comprises a composition configured to prevent and/or reduce tartar, plaque, gingivitis or gum diseases and/or otherwise facilitate oral health or hygiene and a plurality... Agent: Snell & Wilmer L.L.P. (main)

20070292364 - Method for measurably improving oral health: The present invention provides a method to measurably improve oral health. The method includes use of a composition, including one or more active ingredients to measurably improve oral health, a system including the composition and a container encapsulating the composition, and a kit including a plurality of systems. Each system... Agent: Snell & Wilmer L.L.P. (main)

20070292362 - Method for orthodontia care: A composition for orthodontia care, a system including the composition, a kit including multiple systems and methods of using the composition, system, and kit and forming the composition, system, and kit are disclosed. The composition is designed to maintain contact with a portion of a surface for an extended period... Agent: Snell & Wilmer L.L.P. (main)

20070292363 - Method for prevention and treatment of periodontal disease: A composition for prevention and/or treatment of periodontal disease, a system including the composition, a method of using the composition and system, and a method of forming the composition and system are disclosed. The composition designed to maintain contact with a portion of an oral cavity for an extended period... Agent: Snell & Wilmer L.L.P. (main)

20070292365 - Method of mitigating and disrupting tartar buildup: The present invention provides a method to reduce an amount of tartar on a surface and an amount of tartar buildup. The method includes applying a composition configured to maintain one or more active ingredients in contact with a portion of an oral cavity for an extended period of time.... Agent: Snell & Wilmer L.L.P. (main)

20070292366 - System, kit and method for promoting and maintaining oral health: A composition for improving oral health, a system including the composition, a method of using the composition and system, and a method of forming the composition and system are disclosed. The composition is a gel that maintains contact with a portion of an oral cavity for an extended period of... Agent: Snell & Wilmer L.L.P. (main)

20070292370 - Method for improving oral health: A composition for improving oral health, a system including the composition, a kit including multiple systems, a method of using the composition, system, and kit, and a method of forming the composition, system, and kit are disclosed. The composition is designed to maintain contact with a portion of an oral... Agent: Snell & Wilmer L.L.P. (main)

20070292369 - Method for preventing and reducing tartar buildup: A method of reducing tartar on a surface includes providing a composition including at least one active ingredient for reducing tartar, which composition may be provided in a container. The composition is configured to maintain the active ingredient in contact with the surface for an extended time. The composition may... Agent: Snell & Wilmer L.L.P. (main)

20070292368 - Oral care composition: A composition for improving oral health and a method of using and forming the composition are disclosed. The composition includes one or more active ingredients and a carrier configured to maintain the composition in contact with a surface for an extended period of time to promote oral health and hygiene.... Agent: Snell & Wilmer L.L.P. (main)

20070292371 - Composition for promoting and maintaining oral health: A composition for improving oral health and methods of using and forming the composition are disclosed. The composition includes one or more active ingredients and a carrier. The composition is configured to maintain the active ingredient(s) with a surface of an oral cavity for an extended period of time to... Agent: Snell & Wilmer L.L.P. (main)

20070292372 - Gel composition for improving oral health, system including the composition, and methods of using and forming same: A composition for improving oral health, a system including the composition, a method of using the composition and system, and methods of forming the composition and system are disclosed. The composition is a gel that maintains contact with a portion of an oral cavity for an extended period of time... Agent: Snell & Wilmer L.L.P. (main)

20070292374 - Personal care products containing high refractive index esters and methods of preparing the same: wherein R is an aliphatic alkyl group that does not contain an ether group and has a refractive index of greater than about 1.5 at 25° C. Also described are methods of preparing personal care compositions comprising a first phase and a second phase, wherein the second phase contains any... Agent: Flaster/greenberg P.C. 8 Penn Center

20070292376 - Use of a cationically modified hydrolysed starch as a hair fixative: The present invention relates to a hair fixative composition comprising a canonically modified hydrolyzed starch and especially canonically modified hydrolysed starches, hydrolysed to the extend of having a dextrose equivalent of 1 to 6.... Agent: Wood, Herron & Evans, LLP

20070292379 - Hair treating agent comprising corneocyte proteins or corneocyte polypeptides: A hair conditioner that contains 0.05 to 5% by weight of at least one corneocyte protein or corneocyte polypeptide having a relative molar mass ranging between 10 and 40 kDa.... Agent: Paul & Paul

20070292378 - Hair-treatment compositions with corneocyte proteins or polypeptides and silicone(s): Hair-treatment compositions with advantageous properties comprise 0.01 to 5% by weight of at least one corneocyte protein or polypeptide, and 0.05 to 95% by weight of at least one silicone.... Agent: Paul & Paul

20070292381 - Composition and process for coating keratin fibers: The present disclosure relates to a composition for coating keratin fibers, comprising, in a cosmetically acceptable medium: a non-aqueous solvent phase, a first polymer comprising a) a polymer skeleton, having hydrocarbon-based repeating units comprising at least one hetero atom, and optionally b) at least one pendent fatty chain and/or at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070292377 - Oil-based cosmetic composition: An oil-based cosmetic composition having high temperature stability, giving a coating film after evaporation of a solvent having a high gloss, and excellent in forming of a coloring material when the coloring matter, particularly a hair cosmetic composition such as mascara, etc., containing (a) a dextrin fatty acid ester, (b)... Agent: Snider & Associates

20070292383 - Use of surfactant systems for reducing skin-intrinsic enzyme damage: A cosmetic and/or dermatological body cleaning preparation with a reduced tendency toward damaging skin-intrinsic enzymes, containing a surfactant system consisting of (1) alkyl ether sulfate, (2) alkyl amidopropyl betain, (3) another surfactant selected from the group of alkyl polyglucosides, ethoxylated triglycerides and the salts of citric acid polyglycol esters, in... Agent: Greenblum & Bernstein, P.L.C

20070292384 - Water soluble micelle-forming and biodegradable cyclotriphosphazene-taxol conjugate anticancer agent and preparation method thereof: c

20070292385 - Phospholipase inhibitors localized in the gastrointestinal lumen: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in... Agent: Ilypsa-mcandrews C/o Mcandrews, Held & Madison Street

20070292387 - Transmucosal delivery of pharmaceutical active substances: Provided is a conjugate including a pharmacologically active substance covalently bound to chitosan or its derivative and a method for transmucosal delivery of a pharmacologically active substance using the same. Specifically, a conjugate includes a pharmacologically active substance covalently bound via a linker to chitosan; and a pharmaceutical composition for... Agent: The Rafferty Patent Law Firm

20070292386 - Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents: The present invention relates to compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more adjuvants. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one adjuvant, which enhances the immune response to the antigenic or immunogenic agent,... Agent: Becton, Dickinson And Company (alston & Bird LLP)

20070292390 - Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies: The invention provides polypeptides that bind with an epitope of the gp41 subunit of the HIV-1 envelope glycoprotein, as well as polypeptides comprising the aforementioned epitopes. The invention also provides methods of inhibiting an HIV infection in a mammal using the polypeptides of the invention, as well as compositions comprising... Agent: Leydig, Voit & Mayer, Ltd.

20070292389 - Method for the purification and amplification of tumoral stem cells: The invention concerns a method for the purification and amplification in the undifferentiated state of tumoral stem cells form solid tumours which are most resistant to conventional therapies, aiming at devising new tumour markers and therapeutic targets both for early diagnosis and for targeted therapeutic strategies.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070292388 - Method of generating islet beta-cells from exocrine pancreatic cells: The present invention discloses an in vitro method wherein mammalian beta-cell differentiation can be induced in dedifferentiated exocrine pancreatic cells in a medium comprising ligands of the EGF receptor and the GP130 receptor, such as EGF and LIF. Insulin secreting cells, obtainable by this method, provide a means for the... Agent: Bacon & Thomas, PLLC

20070292391 - Stabilized interferon liquid formulations: A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, an amino acid and an antioxidant. Preferably, the interferon is human recombinant IFN-beta.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070292394 - Treatment of non-neuronal cancer using hsv-1 variants: A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment... Agent: Klarquist Sparkman, LLP

20070292395 - Use of viruses and virus-resistant microorganisms for controlling microorganism populations: A lytic virus specific for a target strain of a microorganism and substantially free of undesirable genes may be utilized in processes including control of populations of microorganisms. The virus may include a host-range mutant, or “h-mutant.” A method for generating virus includes growing virus-resistant variants of a target strain... Agent: Trask Britt

20070292402 - Lyophilised lactic acid bacteria and bifidobacteria products with a high degree of dispersibility: Lyophilised lactic acid bacteria and bifidobacteria products are described, characterised by a high degree of dispersibility thanks to the use of polyalcohols and/or sugars as dispersing agents. The liquid dispersions of these lyophilised products are characterised by a high degree of stability.... Agent: Lucas & Mercanti, LLP

20070292396 - Combination therapy with oncolytic adenovirus: The present invention involves compositions and methods for treating cancer using a combination of cell cycle modulating agent(s) and anticancer agents or therapies, particularly S-phase specific therapies.... Agent: Fulbright & Jaworski L.L.P.

20070292397 - Method for the detection and neutralization of bacteria: The present invention relates to the identification of bacteria present at the site of infection and the treatment of the infection using bacteriophage. In certain embodiments, the present invention provides methods and compositions for treating bacterial infections by identifying at least one bacteria species in the infection based on its... Agent: Kinetic Concepts, Inc. Legal Department Intellectual Property

20070292399 - Co-culture of placental stem cells and stem cells from a second source: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem... Agent: Jones Day

20070292400 - Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor: Compositions for application to the skin of individuals in need thereof are provided that include media conditioned by the growth of human embryonic stem cells.... Agent: Biotechnology Law Group C/o Portfolioip

20070292403 - Methods of treating a neurological disorder with creatine monohydrate: The present invention provides methods of treating neurological disorders, such as Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis, by administering creatine monohydrate and dextrose, alone or in combination with an anti-inflammatory compound, to a subject.... Agent: Lahive & Cockfield, LLP

20070292404 - Antimicrobial polymer conjugates: The present invention relates to the conjugation of antimicrobial agents to water-soluble polymers to improve their clinical properties in terms of their pharmacokinetics, pharmacodynamics, and reduced immunogenicity. More specifically, the present invention relates to the conjugation of antimicrobial agents such as lysostaphin to poly(alkylene oxides), such as poly(ethylene glycol) (PEG).... Agent: Medlen & Carroll, LLP

20070292406 - Pharmaceutical composition for preventing and treating restenosis comprising peroxiredoxin 2 protein as an active ingredient and composition for screening therapeutics of restenosis comprising peroxiredoxin 2 gene or its protein product, and method for sc: Disclosed herein is a pharmaceutical composition for the prophylaxis and treatment of restenosis, comprising a peroxiredoxin 2 (Prx II) protein as an active ingredient. Optionally, the composition may contain other active ingredients suppressive of restenosis at the carotid artery, the coronary artery, the peripheral artery, and the renal artery. Also,... Agent: Jhk Law

20070292405 - Uses of erss modulators: The present invention relates to uses of ERβ modulators in the preparation of medicaments for preventing and/or treating hormone dependant cancers and other proliferative disorders, as well as diagnosis of hormone dependant cancers and other proliferative disorders. The present invention also teaches a method of screening agents for their use... Agent: Myers Bigel Sibley & Sajovec

20070292407 - Methods of treatment for meconium aspiration syndrome: The present invention relates to compositions and methods relating to prophylactic treatment and treatment of meconium aspiration syndrome comprising administering to a subject in need of treatment a therapeutically effective amount of acetylcysteine (N-acetyl-L-cysteine). One aspect of the invention relates to pharmaceutical compositions and methods of treatment comprising acetylcysteine and/or... Agent: Medlen & Carroll, LLP

20070292412 - novel genes and markers in type 2 diabetes and obesity: Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene... Agent: Birch Stewart Kolasch & Birch

20070292411 - Antibodies that immunospecifically bind to trail receptors: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptors. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TRAIL receptor antibodies, vectors and host cells containing these... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070292413 - Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070292415 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20070292414 - Compositions enriched in neoplastic stem cells and methods comprising same: A neoplastic stem cell population enriched for expression of the OCT4 transcription factor as well as methods for their identification, isolation and enrichment are described. The OCT4-enriched neoplastic stem cell population is further utilized for the induction and analysis of cancer in an animal. In addition, methods of preventing, abrogating,... Agent: Pearl Cohen Zedek Latzer, LLP

20070292409 - Methods and compositions for producing insulin sensitization: The invention herein provides a mode of treating metabolic syndrome, which includes Type 2 diabetes mellitus and insulin resistance in human and other subjects by identifying and administering an insulin sensitizing compound which modulates GRK2 function in the insulin signaling pathway. The invention also provides polynucleotides, polypeptides, vectors, cells, tissues... Agent: Biotactica, LLC

20070292410 - Methods and compositions to treat and detect misfolded-sod1 mediated diseases: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1)... Agent: Bereskin And Parr

20070292408 - Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences: The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the... Agent: Lahive & Cockfield, LLP

20070292417 - Chimeric allgraft tolerance induction, monitoring and maintenance: A method is provided for inducing donor-specific tolerance and/or mixed donor-recipient chimerism in an allograft transplant recipient, by administering to a recipient of an allograft a therapeutically effective amount of an immunosuppressive agent that depletes T cells; administering to the recipient of the allograft a therapeutically effective amount of anti-αβ... Agent: Medlen & Carroll, LLP

20070292416 - De-immunized anti-cd3 antibody: Antibodies or functional antibody fragments that recognize or interfere with the production of a component of the CD3 antigen complex are de-immunized.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070292420 - Anti-il-6 antibodies, compositions, methods and uses: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions,... Agent: Philip S. Johnson Johnson & Johnson

20070292418 - Compositions and methods for immunotherapy: The invention relates to immunotherapeutic compounds, compositions that include such compounds, and methods of using the compounds, for example, to treat an individual having, at risk for, or previously treated for a cancer.... Agent: Wilmerhale/boston

20070292419 - Treatment with anti-erbb2 antibodies: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or... Agent: Genentech, Inc.

20070292421 - Method for treating preeclampsia: Disclosed are methods and compositions for treating or inhibiting the onset of preeclampsia through administration to a pregnant mammal in need of such a treatment an effective amount of at least one C5a inhibitor. The C5a inhibitor may be co-administered with other active agents.... Agent: Dr. Bruce B. Feinberg

20070292422 - Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological... Agent: Seattle Genetics, Inc.

20070292423 - Method of defining the differentiation grade of tumor: The present invention relates to a method of defining the differentiation grade of tumor by selecting genes and/or proteins whose expression level correlates with each differentiation grade of tumor, measuring the expression of the genes and/or proteins of human tumor tissues in each differentiation grade. The present invention also relates... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070292425 - Chlamydia pmp proteins, gene sequences and uses thereof: The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrom, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070292426 - Methods and compositions based on shiga toxin type 1 protein: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of... Agent: Clark & Elbing LLP

20070292424 - Novel human eosinophil-derived basic protein: The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and... Agent: Foley And Lardner LLP Suite 500

20070292427 - Substantially pure steroidogenesis inducing peptide and uses thereof: Provided are compositions and methods for increasing the production of steroid hormones in testes, ovaries, or adrenal glands in a subject in need thereof. Also provided are compositions and methods for inhibiting proliferation of ovarian, testicular, prostate gland, breast, and liver cancer cells.... Agent: Needle & Rosenberg, P.C.

20070292428 - Antibodies against cancer produced using masked cancer cells as immunogen: This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to human red or white blood cells or normal tissue cells. Antibodies of the... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070292429 - Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce... Agent: Ryan Kromholz & Manion, S.c.

20070292430 - Pyrrolo[2,3-d]pyrimidine compounds: wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer,... Agent: Pharmacia Corporation Global Patent Department

20070292431 - 4-1bb receptors are expressed on regulatory t-cells: The thymus-derived CD4+CD25+T cells belong to a subset of regulatory T cells potentially capable of suppressing the proliferation of pathogenic effector T cells. Intriguingly, these suppressor cells are themselves anergic, proliferating poorly to mitogenic stimulation in culture. The inventors have found that the 4-1BB co-stimulator receptor, best known for promoting... Agent: Banner & Witcoff, Ltd.

20070292432 - Immunoglobulins: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070292433 - Compounds and methods for treatment of chemotherapy-induced anemia: The invention relates to methods and compounds for treating chemotherapy-induced anemia. In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.... Agent: Fibrogen, Inc. Intellectual Property Department

20070292434 - Fibronectin iii domain as leptin receptor antagonists: The invention relates to a new type of leptin receptor antagonist, which is able to prevent leptin signaling without preventing the binding of leptin to the leptin binding domain. More specifically, the invention relates to the use of a part of the leptin receptor to prevent the leptin-dependent activation of... Agent: Trask Britt

20070292435 - Ligand for herpes simplex virus entry mediatior and methods of use: A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070292436 - Immunogenic proteoliposomes, and uses thereof: An immunogenic proteoliposome containing a transmembrane protein or oligomeric complexes containing such proteins, including viral envelope glycoproteins, in a lipid membrane around an elliptoid or spherical shape. The shape preferably also contains an attractant such as streptavidin or avidin and the lipid membrane contains a moiety that binds to the... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20070292437 - Chlamydia pmp proteins, gene sequences and uses thereof: The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefor, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070292439 - Antagonist anti-cd40 monoclonal antibodies and methods for their use: Compositions and methods for inhibiting CD40-directed activities that are mediated via the binding of C4BP to CD40 are provided. The compositions of the invention include anti-CD40 antibodies, or antigen-binding fragments thereof, that have the following characteristics: 1) are free of significant CD40 agonist activity when bound to CD40 antigen; and... Agent: Novartis Vaccines And Diagnostics Inc.

20070292440 - Cd154 blockade therapy for pancreatic islet tissue transplantation: Methods and compositions for inhibiting rejection of insulin-producing tissue in a graft recipient, as well as methods and compositions for prolonging graft survival or function; for reversing graft rejection or restoring function of an impaired graft; and, for inducing immunological tolerance to grafted, insulin-producing tissue. The present methods and compositions... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070292438 - Novel gene disruptions, compositions and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO240, PRO943, hu A33, PRO230, PRO178, PRO1199, PRO4333, PRO1336, PRO19598, PRO1083, hu TRPM2 or PRO1801 genes.... Agent: Genentech, Inc.

20070292441 - Tumor specific antibody: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The... Agent: Bereskin And Parr

20070292442 - Antibody purification: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.... Agent: Lahive & Cockfield, LLP/abbott

20070292443 - Polypeptides with multifunction: Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide... Agent: Yi Li

20070292444 - Peptides for treatment and diagnosis of bone diseases: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070292445 - Delivery system for transdermal immunization: The present invention relates to a delivery system for transdermal immunization. More particularly, the invention relates to a delivery system for effective topical administration of antigens using an apparatus that generates micro-channels in the skin of a subject. The delivery system is useful for immunization against bacterial, viral, and fungal... Agent: Winston & Strawn LLP Patent Department

20070292446 - Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin: A pharmaceutical composition for sublingual, buccal or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoim-mune disease.... Agent: Venable LLP

20070292447 - Peptide minotopes of mycobacterial mannosylated lipoglycans and uses thereof: The present invention relates to the identification of antigenic and immunogenic peptide-based mimicry of mannose-containing cell-wall compounds characterizing mycobacterial infectious agents, such as Mycobacterium tuberculosis. Amino acid molecules which are mimotopes of mannosylated lipoglycans, such as lipoarabinomannan (ManLAM), including at least one of the following characteristics: (a) being capable of... Agent: Nath & Associates

20070292448 - Preloaded dendritic cell vaccines for treating cancer: This disclosure provides a technology for making a dendritic cell vaccine suitable for high volume manufacturing and distribution. Human stem cells are differentiated in a multi-step protocol to generate cell populations bearing a dendritic cell phenotype. The cells are loaded by pulsing with a specific tumor antigen, or by activation... Agent: Geron Corporation

20070292449 - Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against... Agent: The Webb Law Firm, P.C.

20070292450 - Immunogenic compositions of staphylococcus epidermidis polypeptide antigens: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compostions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using... Agent: Wyeth Patent Law Group

20070292451 - Medical herb composition for promoting the growth of hair a mammal and the manufacturing method thereof: A medical herb composition for promoting the growth of hair of a mammal is disclosed. The medical herb composition comprises: an extract of Sophorae Radix; an extract of at least one vital-energy-invigorating plant; and an extract of at least one blood-nourishing plant. Moreover, the weight percentage of the extract of... Agent: Bacon & Thomas, PLLC

20070292452 - Vaccine compositions which are obtained from streptomyces: The present invention relates to the field of immunology, specifically to the control of infectious diseases caused by mycobacteria using vaccines developed from live strains of Streptomyces, expressing or not antigens of M. tuberculosis, which demonstrated their protective capacity against challenge with BCG and M. tuberculosis after being administered by... Agent: Lackenbach Siegel, LLP

20070292453 - Rna virus vaccines and methods: The invention is a vaccine, and method of vaccination, against RNA viruses, including RNA viruses in the family Flaviviridae, which includes for example West Nile Virus, Yellow fever virus, Dengue fever virus, Hepatitis C virus, Pestiviruses, Bovine viral diarrhea virus, and Classical Swine fever virus, wherein the vaccine comprises the... Agent: Dunlap Codding & Rogers, P.C.

20070292454 - Therapeutic calcium phosphate particles and methods of manufacture and use: Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such... Agent: Kenyon & Kenyon LLP

20070292455 - Attenuation of cytomegalovirus virulence: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.... Agent: Johnathan Klein-evans

20070292456 - Formulations containing an immune response modifier: Pharmaceutical formulations in an aqueous (preferably, sprayable) formulation including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, and 1H-imidazo dimers... Agent: 3m Innovative Properties Company

20070292457 - Electrical nutritional supplement: A object of the present invention is to provide a novel system whereby an enteral nutrient or an enriched liquid food can be solidified so that it can be easily administered within a short period of time without liguefying in the body to thereby lighten a care-giver's burden in tube... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070292463 - Compositions and methods comprising energizable particles for health use: The present invention provides a composition comprising a topical composition base and a plurality of particles selected from the group consisting of magnetic particles, particles comprising microcircuit chips, and combinations thereof. The composition can further comprise one or more active agents. The particles and/or active agent(s) can optionally be encapsulated... Agent: Diehl Servilla LLC

20070292458 - Dentifrice compositions containing zeolites: A dentifrice composition comprises a crystalline aluminosilicate as a cleaning agent having an average crystallite size below 0.2 μm. The aluminosilicate may be a P zeolite having a crystallite size below 0.1 μm and agglomerate sizes below 2.5 μm, even when dried to a moisture content below 20% by weight.... Agent: Jones Day

20070292459 - Halloysite microtubule processes, structures, and compositions: A composition for use in the delivery of a first active agent and a second active agent, the first active agent being sequentially deliverable after the second active agent, the composition comprising hollow mineral microtubules, each of the hollow mineral microtubules having a length, and opposing ends; and including a... Agent: Basch & Nickerson LLP

20070292461 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent... Agent: Wilmerhale/boston

20070292460 - Product release system to atomize non-liquid or highly viscous cosmetic compositions: A product release system to atomize cosmetic compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition. The atomization is done using the capillary and the composition is non-fluid at 77° F. (25° C.) or has a viscosity greater than 0.0007... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070292462 - Surfactant, and an emulsion-type cosmetic composition and a liposome containing said surfactant: wherein R represents a saturated or unsaturated acyl group having 8-22 carbon atoms, and may have a hydroxyl group or other substituents, and an emulsion-type cosmetic composition comprising said surfactant and a water-soluble polymer. The surfactant of the invention has excellent surface activity and safety. Also, the emulsion-type cosmetic composition... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070292464 - Fibers and sheet-form textiles provided with insect-repellent finishes: The present invention relates to fibers and sheet-form textiles which are characterized in that they are finished with mixtures of (a) microencapsulated insect repellents and (b) binders.... Agent: Cognis Corporation Patent Department

20070292465 - Eutectic biocide compositions and formulations: Binary or greater mixtures of biocides which exist in the form of eutectic blends which range from damp blends to liquid blends are described. Mixtures of phenolic biocides are preferred. The biocides are useful in the formulation of disinfectant compositions for industrial and domestic use.... Agent: Clariant Corporation Intellectual Property Department

20070292466 - Mold inhibiting mixture and method for application of a mold inhibiting emulsion: A mold inhibiting mixture including hydrated lime, (CaH2O2), also referred to as calcium hydroxide, mixed with a viscosity enhancing agent, lemongrass oil and an emulsifying agent. In a preferred embodiment, the viscosity enhancing agent includes a base oil. A mold inhibiting emulsion is formulated by mixing water with the mold... Agent: Holland Law Office P.l.l.c.

20070292467 - Multi-component insect attractant: Embodiments of the present invention employ insect-attracting liquid mixtures, solid mixtures, liquid solutions, and solid solutions that include two or more insect-attracting substances or compounds with different volatilities. The insect-attracting-substance embodiments of the present invention, upon controlled vaporization or release, create a multi-component, three-dimensional plume that leads insects to the... Agent: Olympic Patent Works PLLC

20070292468 - Coated jewelry articles to reduce skin irritation: Skin irritation is a common problem to those who wear potentially skin irritating jewelry such as pierced earrings. The present invention provides a coated-medicated jewelry article that thwarts skin irritation and may provide relief for irritated skin. The coating contains a film-former and optionally a medicament.... Agent: Frenkel & Associates

20070292470 - Implantable medical devices and methods for making the same: Disclosed herein are polymeric implantable medical devices and methods for making the same. Specifically, disclosed are polymeric implantable medical devices produced through the use of solvent casting methods.... Agent: Medtronic Vascular, Inc.IPLegal Department

20070292469 - Antimicrobial composition: A stabilized antimicrobial composition comprising (a) polymeric polyquaternary ammonium compounds and (b) an antimicrobial metal, such as elemental silver, alloys thereof or silver compounds. The antimicrobial composition may be used as a stand-alone composition, in an antimicrobial formulation, or in combination with medical articles or medical devices. The antimicrobial composition... Agent: Philip S. Johnson Johnson & Johnson

20070292472 - Methods, systems and devices for the delivery of endoluminal prostheses: Described are devices, methods, and systems for achieving occlusion of vascular vessels. Further described are certain reduced or low profile procedures and devices for the percutaneous occlusion of the saphenous vein, such as in the treatment of a varicose vein condition caused by venous reflux.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070292471 - Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof: The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a... Agent: Leydig, Voit & Mayer, Ltd.

20070292473 - Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parenteral administration and preparation process: A method for implanting or inserting a solid or semisolid formulation containing at least one active principle uses a device comprising one part set inside the body of the patient and which conditions the solid or semisolid form, brings these conditioning action to the deposit site, injects or inserts in... Agent: Young & Thompson

20070292474 - Structure for modulating intraocular pressure: Embodiments of the present invention are directed to three-dimensional porous structures for modulating intraocular pressure. The structures can include a mixture of copolymers, for example, collagen and glycosaminoglycan.... Agent: Venable LLP

20070292475 - Controlled release microparticles: Formulations for controlled, sustained release of biologically active agents for the treatment of ocular disorders have been developed. These formulations are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. The microparticles are characterized by low... Agent: (osi) Eyetech, Inc.

20070292476 - Delivery of ophthalmologic agents to the exterior or interior of the eye: The present invention provides intraocular polymer delivery compositions based on biodegradable polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids. The compositions can be formulated as an implantable solid or as a liquid dispersion of polymer particles for sustained delivery of ophthalmologic agents dispersed... Agent: Dla Piper US LLP

20070292477 - Association of antimicrobial compounds with surfaces and polymers: The invention describes antimicrobial silicone oligomers or polymers comprising a silicone oligomer or polymer associated with at least one compound of formula (I). Also described are methods of associating compounds of formula (I) to surfaces and products thereof.... Agent: Nixon & Vanderhye, PC

20070292478 - Medical implant provided with inhibitors of atp synthesis: An implant provided with a composition having at least one type of inhibitor of ATP synthesis is disclosed. The implant is useful for preventing or treating benign or malignant cell proliferation in a duct or a resection cavity of a subject.... Agent: Knobbe Martens Olson & Bear LLP

20070292479 - Film-shaped drug forms for use in the oral cavity (wafers): The present invention describes film-shaped systems capable of transmucosal buccal application and comprising at least one steroid hormone from the group of the androgens, the progestogens and the oestrogens, 10-70% by weight of a cyclodextrin or a cyclodextrin derivative, and a film-forming agent disintegrating in an aqueous medium.... Agent: Millen, White, Zelano & Branigan, P.C.

20070292482 - Delivery system: A delivery system for ingestible components is described. The delivery system comprises at least one orally soluble film but often comprises more than one orally soluble film. The orally soluble films within the delivery system comprise a different biologically active component or mixture of biologically active components so that a... Agent: Unilever Intellectual Property Group

20070292480 - Delivery system for ingestible components: A delivery system for ingestible components is described. The delivery system comprises at least one orally soluble film but often comprises more than one orally soluble film. The orally soluble films within the delivery system comprise a different biologically active component or mixture of biologically active components so that a... Agent: Unilever Intellectual Property Group

20070292481 - Packaging of food products with pullulan films: An edible article comprises a food product and a film that encloses the food product. The film comprises a major amount of pullulan on a dry solids basis, and a minor amount of at least two of glycerol, propylene glycol, and sorbitol. The edible article can be manufactured by preparing... Agent: Williams, Morgan & Amerson

20070292483 - Reducing muscle soreness with glucosamine compositions: Edible compositions, such as sports drinks which limit muscle soreness, and methods of making and using the same are provided. Existing food products, such as sports beverages are commonly used during exercise to quickly replace fluids and electrolytes lost by sweating and/or to supply a boost of carbohydrates to improve... Agent: Banner & Witcoff, Ltd. And Attorneys For Client No. 006943

20070292485 - Polyol ester compounds: Disclosed are polyol esters comprising a polyol having at least one hydroxyl group esterified to at least one compound having a carboxyl group. Methods of making the polyol ester compounds are also disclosed. The invention also relates to feed compositions comprising polyol ester compounds.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070292484 - Treated pigskin pet treat: The present invention relates to a pet treat having at least two distinctly treated pieces of pigskin and to a method of making it. In particular, the pet treat includes a piece of defatted pigskin and a piece of smoked pigskin.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070292487 - Anti-inflammatory dissolvable film: Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom.... Agent: Law Offices Of Arthur E. Jackson

20070292486 - Novel polymer-nano/microparticle composites: Polymeric materials, including polymers and polymer-composite materials, are useful for a variety of applications including biocidal coatings. Representative examples include a composite of silver salt particles and an ionic polymer. A novel process was developed whereby the counter-ion of an ionic polymer is precipitated as a metal salt, so as... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070292488 - Method for treatment of wound treatment using aganocides: Provided herein is a method for the treatment of a wound using a wound treatment regimen for treating a chronic wound, the regimen comprising: a) applying reduced pressure to the wound; and b) treating the wound with a substantially non-toxic, non-irritating inorganic aganocide composition while applying reduce pressure to the... Agent: Heller Ehrman LLP

20070292489 - Method for treatment of wound treatment using aganocides: Provided herein is a method for the treatment of a wound using a wound treatment regimen for treating a chronic wound, the regimen comprising: a) applying reduced pressure to the wound; and b) treating the wound with a substantially non-toxic, non-irritating organic aganocide composition while applying reduced pressure to the... Agent: Heller Ehrman LLP

20070292490 - Production of tissue factor in plants: The instant invention provides transgenic plants that express mammalian, e.g., human, recombinant tissue factor (rhTF) as well as methods for making rhTF. The invention further provides rhTF or functional fragment thereof that are obtained from a transgenic plant. The invention also provides methods of treating a subject using the rhTF... Agent: Edwards Angell Palmer & Dodge LLP

20070292491 - Adhesive patch: A patch for covering a portion of the anatomical surface of a living being, said patch being able to adhere to the skin or mucosa, and/or a wound, said patch comprising a backing layer and a layer of a skin-friendly adhesive for adhering to the skin or mucosa, said adhesive... Agent: Jacobson Holman PLLC

20070292492 - Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery: Pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of tetracycline antibiotic to at least one target tissue are described and methods for administering tetracycline antibiotic via iontophoresis.... Agent: Elmore Patent Law Group, PC

20070292493 - Pharmaceutical composition and method for the transdermal delivery of calcium: The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic... Agent: Perret Doise A Professional Law Corporation

20070292495 - Nanoshells for drug delivery: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.... Agent: Squire, Sanders & Dempsey LLP

20070292494 - Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds: Methods for preferentially delivering an active agent intracellularly to a reservoir cell that is infected with or susceptible to infection with an infectious agent, such as HIV. The active agent is part of a lipid-active agent complex that has a targeting ligand, such as a CTL/CTLD receptor-specific anchor, on its... Agent: Moore & Van Allen PLLC

20070292496 - Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics: The present invention involves the preparation of a pharmaceutical liposomal system in an aqueous solution which contains a substance or polymer with mucomimetic and/or mucoadhesive properties. Due to the components and characteristics of the formulation described in this present patent it can be used as a precorneal tear film substitute.... Agent: Ladas & Parry LLP

20070292497 - Method for treating micrometastatic tumors: An adjuvant chemotherapeutic method for treatment of micrometastases is described. The method comprises administering, to a subject previously treated for resection or reduction of a primary tumor, a chemotherapeutic agent entrapped in liposomes, the liposomes having a coating of hydrophilic polymer chains and a targeting ligand that specifically binds to... Agent: Philip S. Johnson Johnson & Johnson

20070292498 - Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers: Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent, a sleep aid and acetaminophen, ibuprofen, aspirin or naproxen are described. Methods are described for treating gastric acid related disorders and inducing sleep, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, a sleep aid and... Agent: Wilson Sonsini Goodrich & Rosati

20070292500 - Novel extended release composition of venlafaxine hydrochloride containing polyvinyl acetate: Extended release pharmaceutical composition of Venlafaxine hydrochloride comprising a pharmaceutically acceptable capsule containing minitablets. The minitablets comprise from about 20% to about 70% by weight effective amount of Venlafaxine hydrochloride, polyvinyl acetate, one or more pharmaceutically acceptable excipients. The minitablets have diameter from about 1 mm to 5 mm and... Agent: Merchant & Gould PC

20070292499 - Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride: The present invention relates to a process for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride by dry method.... Agent: Ranbaxy Inc.

20070292501 - Chewable soft gelatin capsules: The present invention is directed to compositions and methods of delivery of fill materials containing active agents, optionally dissolved or suspended in a suitable carrier, encapsulated in a chewable soft gelatin capsule.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070292502 - Chitosan-embedded or encapsulated capsule: The present invention relates to a chitosan-embedded or encapsulated capsule, which comprises a chitosan content which is chitosan, a salt thereof, or a derivative thereof, and an edible gum embedding or encapsulating the content.... Agent: Ladas & Parry

20070292503 - Oral pharmaceutical composition of poorly water-soluble active substance: An oral composition of Benzazepin-1-acetic acid derivatives is provided comprising: a) an active compound in an amount of between 10 and 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) optionally comprising auxiliary materials an amount... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070292504 - Pharmaceutical formulation containing a release rate controlling composition: Pharmaceutical formulations suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a base salt of a compound of Formula (I) and a release rate controlling composition comprising a solubilizing agent, a gelling agent, and a water soluble filler; wherein R1, R2, R3... Agent: Merck And Co., Inc

20070292505 - Controlled release alfuzosin hydrochloride formulation: In certain embodiments the invention is directed to a single layer controlled release pharmaceutical formulation comprising a tablet consisting of a single layer matrix comprising a therapeutically effective amount of alfuzosin or a pharmaceutically acceptable salt thereof dispersed in a controlled release material, wherein the formulation following single dose administration... Agent: Davidson, Davidson & Kappel, LLC

20070292506 - Sustained release formulations: The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is... Agent: Foley & Lardner LLP

20070292508 - Orally disintegrating dosage forms: The present invention is directed to orally disintegrating dosage forms comprising lipid coated substrates and silicified excipients. The use of silicified excipients in the orally disintegrating dosage form along with lipid coating of active agents, allows for improvements in the ability to prepare these dosage forms. Further, the dosage form... Agent: Hoffmann & Baron, LLP

20070292507 - Supportive treatment of liver disease: The invention provides a composition and method for treatment of a subject suffering from liver disease comprising the oral administration of a slow release formulation of calcium channel blocker such as diltiazem and thiamine which is also an antioxidant which is relatively hydrophilic when compared with the calcium channel blocker.... Agent: Bio Intellectual Property Service (bio Ips)

20070292509 - Enteric coated granule and method for preparing the same: The present invention is an enteric coated granule having controlled dissolution in water even at a small coating amount; and a preparation method thereof. More specifically, provided are an enteric coated granule comprising a raw granule or a granule comprising a raw granule and at least one layer covering the... Agent: Alston & Bird LLP

20070292510 - Enteric coated particles containing an active ingredient: Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer comprised of polymeric composition having a Tg less than about 40° C. that substantially covers the core; and a second coating layer, which... Agent: Philip S. Johnson Johnson & Johnson

20070292511 - Duloxetine hydrochloride delayed release formulations: Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine hydrochloride, a separating layer and an enteric layer comprising at least one of methacrylic acid copolymer and hydroxypropyl methyl cellulose phthalate.... Agent: Kenyon & Kenyon LLP

20070292512 - Solid oral dosage form containing an enhancer: The invention relates to a pharmaceutical composition, particularly oral dosage forms, comprising a DAC inhibitor in combination with an enhancer to promote absorption of the DAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or derivative thereof having a carbon chain length of from... Agent: Synnestvedt & Lechner, LLP

20070292513 - Chemical compounds: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070292514 - Bioengineered intervertebral discs and methods for their preparation: A bioengineered IVD for disc replacement has been developed that has mechanical and structural support characteristics similar to those of native IVD. Extracellular matrix (ECM) provides support to living cell components and interacts with the living cellular components during the fabrication process without introducing toxicity. The composition can be produced... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070292516 - Multifunctional biocompatible hydrophilic gel and the method of gel manufacture: Multifunctional biocompatible hydrophilic gel contains, in % (w/w), acrylamide—1.95-8.0, methacrylamide—0.54-3.0, 2-hydroxyethyl methacrylate −0.003-0.4, N,N′-methylene-bis-acrylamide—0.006 - 0.6 and water-q.s. to 100. The hydrophilic gel is produced by co-polymerization of the above mentioned monomers in water medium in the presence of a peroxide initiator of polymerization in three stages which include (1)... Agent: Ladas & Parry

20070292515 - Solid dosage form containing a taste masked active agent: A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and release the taste masked active agent. The disintegrable film includes at least one water soluble polymer... Agent: Novartis Corporate Intellectual Property

20070292517 - Delivery systems for antacids: Oral gel delivery systems for antacids are provided comprising an ingestible matrix within which one or more antacid is substantially uniformly and completely dispersed. The delivery systems may optionally include one or more other functional ingredients that complement or enhance the function of antacids within the body.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070292518 - Nanoshell therapy: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a vascular condition are provided.... Agent: Squire, Sanders & Dempsey LLP

20070292519 - Method of producing a nicotine medicament and a medicament made by the method: A method of producing a nicotine medicament for use in an inhaler comprises combining a nicotine formulation, a sugar and a liquid carrier including water to produce a flowable mixture and drying the flowable mixture at conditions to produce particles of the nicotine medicament suitable for delivery to the alveoli... Agent: Bereskin And Parr

20070292520 - Pulmonary insulin crystals: The present invention provides methods and compositions for treating diabetes by administering insulin or an insulin analog via a pulmonary route, wherein the insulin or insulin analog is in crystalline form with a diameter below 10 microns when recovered from a solution having a pH between 7.0 and 9.5. The... Agent: Novo Nordisk, Inc. Patent Department

20070292522 - Method for forming microcapsules with multiple shell layers: A method for forming microcapsules comprises the steps of: forming a core; enclosing a first, a second and a third layer of shells sequentially; wherein the microcapsules has one of the three properties of anti-ultraviolet and can endure a high temperature of 280° C.; and temperature sensitive and color changed... Agent: Jeh-yi Chiu 235 Chung-ho

20070292521 - Oral encapsulated preparation for aquatic animals: An oral encapsulated preparation for aquatic animals, is an water/oil/water type encapsulated preparation which comprises on a weight basis: 50 to 80% of aqueous phase containing water-soluble active agent; 20 to 50% of oily phase containing one or more types of oil; 1 to 5% of the first emulsifying agent;... Agent: Wpat, PC Intellectual Property Attorneys

20070292524 - Delivery vehicle containing nanoparticles: The present invention is directed to a delivery vehicle containing nanoparticles. The present invention is further directed to a pharmaceutical composition, comprising said drug delivery vehicle. Further, the invention pertains to a method for manufacturing of said delivery vehicles as well as to the use of these vehicles in medicine.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070292523 - Dihydropyrimidine formulations: A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having an encapsulating medium, and the mincapsules containing a dihydropyrimidine such as Nimodipine as an active ingredient.... Agent: Jacobson Holman PLLC

20070292525 - Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed... Agent: Foley And Lardner LLP Suite 500

20070292526 - Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed... Agent: Foley And Lardner LLP Suite 500

20070292527 - Composition for the cosmetic treatment of age-related dermatological symptoms: A composition comprising an extract of a deep sea fish; and an extract of rooibos aspalathus linearis); and optionally an extract of bearberry (arctostaphylos uva-ursi) as active components thereof; and optionally one or more fillers or ancillary agents conventionally used in the formulation of compositions is provided. Upon administration, the... Agent: James C. Wray

20070292528 - Kcnma1 as a therapeutic target in cancer treatment: The present invention pertains to a treatment of cancer, particularly prostate cancer, by blocking the large conductance, Ca2+-activated potassium channel KCNMA1 Embodiments of the invention include methods of detecting the level of expression of KCNMA1, methods for treating patients with prostate cancer, and methods of discovering drugs for treating cancer.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20070292529 - Strontium compositions and methods of treating osteoporotic conditions: A therapeutic dosage form and method for treating an osteoporitic condition is described. The therapeutic dosage form comprises a divalent cationic source of strontium, vitamin B6, vitamin B12 and folic acid or folate. The method comprises administering to a subject in need thereof a therapeutic dosage form comprising a divalent... Agent: Hutchison Law Group PLLC

20070292530 - Topical composition and method for the treatment and prophylaxis of dermal irritations: A composition and method for the prevention and therapeutic treatment of skin conditions and disorders are disclosed. The composition and method of the invention are particularly directed to the treatment and prevention of dermal irritations. These irritations include, for example, psoriasis, eczema, ichthyosis, pruritus, dryness and dermatitis, which may cause... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070292531 - Composition for oral use and methods for application of same: A bactericidal composition for improving oral health and a method of using and forming the composition are disclosed. The composition includes one or more active ingredients and a carrier configured to maintain the composition in contact with a surface for an extended period of time to promote oral health and... Agent: Snell & Wilmer L.L.P. (main)

20070292533 - Copper lowering treatment of autoimmune diseases: The present invention relates generally to the field of prophylaxis and therapy for autoimmune diseases. In particular, the present invention is related to agents that can bind or complex copper, and to the use of these agents in the prevention and/or treatment of autoimmune diseases such as rheumatoid arthritis, systemic... Agent: Casimir Jones, S.c.

20070292532 - Vanadium compounds as inhibitors of phosphatases: Novel Vanadium compounds are described as well as their use as inhibitors of phosphatases, particularly inositol phosphatases, The use of the compound in the treatment of nerodegenerative diseases is also described.... Agent: Elmore Patent Law Group, PC

20070292534 - Antacid and breath freshening composition: v

20070292535 - Strontium compositions and methods of treating arthritic and or osteoporitic conditions: A therapeutic composition and method for treating symptoms or etiology of arthritic conditions by administering a divalent cationic source of strontium, para-aminobenzoic acid and α-lipoic acid is described. In addition, a therapeutic composition and method for treating symptoms or etiology of arthritic conditions by administering a divalent cationic source of... Agent: Hutchison Law Group PLLC

20070292536 - Composition and method for treating patients with high neurotransmitter levels: A patient having high neurotransmitter levels is treated by administering an effective amount of a treatment composition comprising Rhodiola Rosea and phosphatidylserine in a pharmaceutically acceptable carrier.... Agent: Ronald L. Hofer

20070292537 - Method and composition for reducing appearance of wrinkles: The present invention provides a cosmetic composition having a cosmetically acceptable vehicle and one or more gap junction inhibitors and/or one or more choline acetyl transferase (CAT) inhibitors in an amount effective for reducing the appearance of deep wrinkles on the skin. Also provided is a method of reducing the... Agent: Joan M. Mcgillycuddy, Esq. Avon Products Inc.

20070292538 - Formulation for hair growth: A composition and method for hair growth are described. The composition may include a dihydrotestosterone blocker and a thyroid source. Alternatively, the composition may include an estrogen source and a thyroid source. The composition may further include a base to facilitate application of the composition. A progestagen source, an antioxidant... Agent: Blakely Sokoloff Taylor & Zafman

20070292539 - Anti-inflammatory cranberry flavonol extract preparations: The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-β-xylopyranoside, quercetin-3-β-glucoside, quercetin-3-α-arabinopyranoside, 3′-methoxyquercetin-3-α-xylopyranoside, quercetin-3-O-(6″-p-coumaroyl)-β-galactoside, and quercetin-3-O-(6″-benzoyl)-β-galactoside. The present invention also embodies the use of those extracts, as well as... Agent: Jones Day

20070292540 - Extracts and methods comprising cinnamon species: The present invention relates to extracts of cinnamon species plant material prepared by supercritical CO2 extractions methods.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070292541 - Method for producing organically-bound vitamin b: The present invention relates to a method for producing organically-bound vitamin B, preferably vitamin B1, B2, B3, B5, B6, B7, B9, B12, or mixtures thereof, in plants, wherein plant seeds are soaked in the solution of the respective vitamin and are cultured to vitamin-B-enriched germ buds by subsequent sprinkling.... Agent: Fulbright & Jaworski L.L.P.

20070292542 - Flaxseeds for body weight management: The present invention relates to methods for reducing fat uptake in the gastrointestinal tract of a mammal in order to prevent a positive energy balance, weight gain, overweight and obesity, and to induce a negative energy balance and weight loss in subjects who wish to reduce their body weight. In... Agent: Knobbe Martens Olson & Bear LLP

20070292543 - Extracts from roots and/or shoots of asparagus officinalis l., their preparation and their use: The present invention relates to a saponine-depleted raw extract and to a saponine-free extract from roots and/or shoots of Asparagus Officinalis L. The invention also relates to the preparation of saponine-depleted raw extracts and saponine-free extracts from roots and/or shoots of Asparagus Officinalis L. and to their use for the... Agent: Greenblum & Bernstein, P.L.C

20070292545 - Anti-infective agents and methods of use: The present invention provides compounds and methods of using of the compounds as anti-infective agents. In a preferred embodiment, the present invention provides wherein R1 is not H when R2 is H and R2 is not H when R1 is H, further wherein R1 is CH(2n+1)O, wherein n is 1-10;... Agent: Whyte Hirschboeck Dudek S.c.

20070292544 - Tea polyphenol composition and method for producing the same: The objective of the present invention is to provide a tea polyphenol composition that has reduced bitterness and astringency while containing catechins with high purity. The present invention provides a tea polyphenol composition, (A) comprising 85% by weight to 95% by weight of catechins, (B) wherein the catechins contains epigallocatechin... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070292546 - Use of botulinum toxin for preparing a drug for preventing hair growth: The use of botulinum toxin for preparing a drug for preventing hair growth is disclosed. A cosmetic method for preventing hair growth is also disclosed.... Agent: Hunton & Williams LLP Intellectual Property Department

20070286802 - Method for testing radiochemical purity of tc-99m-trodat-1: The present invention is to invent a novel method for testing the radiochemical purity of Tc-99m-TRODAT-1 through a high performance liquid chromatography on a widely available C-18 column.... Agent: Troxell Law Office PLLC

20070286803 - Compositions and methods for detecting and treating tumors containing acidic areas: Improved compositions have been developed which are selectively sequestered in acidic areas of tumors. When the compositions contain a radioisotope effective to report the presence of the composition, the compositions are useful for detecting tumors. When the compositions contain radioisotopes effective to kill cells, the compositions are useful for treating... Agent: Teri G. Andrews Attorney At Law

20070286804 - Method, materials and apparatus for investigating asthma using dust mite allergen: The present invention comprises a method, materials and apparatus for investigating asthma in humans using dust mite allergen. The dust mite allergen is prepared to be of a controlled size such that particles are respirable, effectively aerosolized, and deliver a significant amount of allergen. The dust mite allergen is applied... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn:IPDepartment Docket Clerk

20070286808 - Method for display presentation of lymph nodes: In a method for display presentation of lymph nodes of an examination person by a magnetic resonance imaging, a contrast agent with super-paramagnetic iron oxide particles is injected into the examination person, an MR imaging sequence for phase-sensitive acquisition of the lymph nodes of the examination person is implemented, at... Agent: Schiff Hardin, LLP Patent Department

20070286810 - Nanoparticles comprising lanthanide chelates:

20070286809 - Oxygen therapy with ultrasound: A treatment is described for delivering oxygen to tissue, especially hypoxic tissue. A medium saturated with gas is delivered to the tissue. Dissolved gas is transferred from the medium to the tissue. Ultrasound is transmitted to the tissue to enhance the transfer of gas to the tissue.... Agent: Coats & Bennett, PLLC

20070286812 - Nasal formulation: The present invention relates to a novel nasal formulation for nasal hygiene and to improve nasal airflow of people suffering from nasal congestion.... Agent: Bereskin And Parr

20070286813 - Nasal formulation: The present invention relates to a novel nasal formulation for the treatment and prophylaxis of nasal congestion. When an infant is born, its nasal passages are relatively sterile, in time the nasal passages are colonized by fungi, molds and other organisms which compromise the integrity of the nasal and paranasal... Agent: Bereskin And Parr

20070286814 - Stable aerosol pharmaceutical formulations: The present invention provides a stable aerosol pharmaceutical formulation of a beta-agonist, an anticholinergic, or a combination thereof in combination with a cosolvent and optionally a surfactant. The invention also provides a method of making the stable aerosol pharmaceutical formulation and methods of treating bronchoconstriction, asthma and related conditions with... Agent: Michael Best & Friedrich LLP

20070286817 - Treating cystic fibrosis with antibiotics via a swirler delivery: The present invention is directed to a method of treating respiratory disorders by delivering an aerosol composition of an antibiotic drug to the lung alveoli.... Agent: Wyeth Patent Law Group

20070286819 - Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability: Methods of improving the bioavailability of ethinyl estradiol by orally administering to a patient a solid dosage form containing ethinyl estradiol or prodrug thereof where that dosage form releases at least some of the ethinyl estradiol or prodrug thereof in the oral cavity for absorption through the oral mucosa to... Agent: Fitzpatrick Cella Harper & Scinto

20070286821 - Composition with activated carbon in oral treatment: In a personal care daily practice, common human malodor in breath can be treated and eliminated or substantially reduced through the use of a treatment comestible, lozenge, chewing gum or scraper prepared by combining a hardenable natural or artificial sweetener or gum base with an amount of activated carbon effective... Agent: Merchant & Gould PC

20070286824 - Bleed-resistant colored microparticles and skin care compositions comprising them: Bleed-resistant microparticles comprising at least one colorant, a process to produce them, compositions containing them and their use in skin care applications to produce a natural, textured tone effect.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286827 - Optical brighter and uv stabilizer for acrylic enhancements: An artificial nail composition containing multicarbonyl-vinyl containing monomer, polymerization initiator, and optical brightener. The invention also relates to the process of making the nail composition.... Agent: Connolly Bove Lodge & Hutz LLP 1007 North Orange Street

20070286830 - Aluminum compositions of enhanced efficacy having high hplc bands iii and iv: When analyzed by SEC-HPLC at about 10% concentration (i.e., by 2% Al) in water, these compositions exhibit an SEC-HPLC Band I area of less than 10%, a Band III area of at least 20%, with a Band III/II area ratio of at least 0.7, a Band IV area of at... Agent: Arthur J. Plantamura General Chemical Performance Products LLC.

20070286832 - Multi-phase personal cleansing compositions comprising two aqueous phases: The present invention relates to a multi-phase personal-cleansing composition comprising a first aqueous phase and a second aqueous phase packaged in physical contact with one another. The first aqueous phase comprises a surfactant, a salt and water. The second aqueous phase comprises a polymer, a salt and water. The molality... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286834 - Water stream dispersible skin care solid composition: e

20070286835 - Skin external preparation having hexagonal gel structure: Disclosed is a skin external preparation containing stratum corneum intercellular lipids, ceramide, and having a hexagonal gel structure. More particularly, the skin external preparation having the hexagonal gel structure contains, as stratum corneum intercellular lipid components, ceramide and cholesterol or its derivative and/or fatty acid, and as an emulsifying agent,... Agent: Thomas M. Galgano, Esq. Galgano & Associates, PLLC

20070286838 - Tamanu oil products: A dermatological composition which may be used for the topical treatment of the skin, hair, or nails of mammals, comprising tamanu oil, an unsaturated fatty acid, and arnica oil, optionally including Vitamins E and A. The dermatological composition may be combined with other components to form a shampoo, conditioner, lotion,... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20070286801 - Cyclooxygenase-2 selective agents useful as imaging probes and related methods: This invention provides novel cyclooxygenase-2 selective agents that are particularly useful as imaging probes in non-invasive imaging techniques, such as PET and SPECT. Preferred cyclooxygenase-2 selective agents inhibit cyclooxygenase-2 activity with greater potency and specificity than conventional cyclooxygenase-2 inhibitors. Other aspects of the invention include pharmaceutical compositions including the cyclooxygenase-2... Agent: Christie, Parker &hale, LLP

20070286807 - Method of inducing or modulating immune response: The use of axotrophin, also known as MARCH VII to induce or regulate immune response to an antigen whether foreign or self, suitably in a vertebrate, for example a mammal is disclosed. Isolated axotrophin and nucleotides and polypeptides encoded by or derived from axotrophin, compositions containing one or more thereof... Agent: Sutherland Asbill & Brennan LLP

20070286806 - Methods and compositions for modulating a steroid receptor: Methods, compositions, and uses are provided for modulating a steroid receptor or process mediated by a steroid receptor in a cell by administering a polypyridimine tract binding protein-associated splicing factor (PSF) polypeptide, a polynucleotide encoding the polypeptide, an isolated complex of a PSF polypeptide and a steroid receptor, and/or an... Agent: Mary E. Bak Howson And Howson

20070286805 - Methods of validating target for modulating insulin action, screening for modulators of insulin action and therapeutic uses thereof: The present invention provides several assay formats for determining the effect of compounds on one or more metabolism-associated phenotypes in a cell, tissue or animal. The assay formats are based upon the finding that Cbl (e.g., the protooncogene c-Cbl) is an upstream regulator of AMPK activity and ACC activity in... Agent: Quine Intellectual Property Law Group, P.C.

20070286811 - Method for the manufacturing of a diffraction grating structure on the surface of pharmaceutical tablet: A diffractive microstructure (11) is implemented as a security feature in the surface of tablet (4). For this purpose the punches (1a, 1b) comprise a microstructure (11), which during the compression process produce the diffractive microstructure on the surface of the tablet (4), by plastic and/or visco-elastic deformation of the... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070286816 - Drug and excipient aerosol compositions: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a... Agent: Swanson & Bratschun, L.l.c

20070286815 - Medicinal aerosol formulations and methods of synthesizing ingredients therefor: A medicinal aerosol product and process, such as for an HFA metered dose inhaler, wherein at least one of the formulation ingredients is synthesized by running at least part of the chemical reaction to make the ingredient in a hydrofluoroalkane reaction medium.... Agent: 3m Innovative Properties Company

20070286818 - Treating cystic fibrosis with antibiotics via an aerosol drug: A method of treating respiratory disorders by delivering antibiotic to the lung alveoli using an aerosol drug delivery system.... Agent: Wyeth Patent Law Group

20070286822 - Compounds for the treatment of periodontal disease: Compounds, compositions and methods are provided which are useful in the treatment of periodontal disease.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070286820 - Oral care regimen: The invention includes methods of cleaning an oral surface, maintaining oral health and/or increasing oral health. Such methods encompass contacting an oral surface with a primary oral care composition at least once daily, and contacting the oral surface with a periodic oral care composition at least once within a period... Agent: Colgate-palmolive Company

20070286823 - Compositions having anti-dental caries function: The present invention relates to dietary compositions and oral compositions having an anti-dental caries function. The present invention provides dietary compositions and oral compositions having an anti-dental caries functions which contain a buffering agent having a pH buffering action in the oral cavity.... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20070286825 - Cosmetic agents and methods for the preparation thereof: A cosmetic agent is disclosed comprising a cosmetically useful group bound to an amino functional group by a linking moiety. The linking moiety comprises an alkylidene or an arylidene group bearing two carboxyl groups. The cosmetically useful group is bound to one carboxyl group of the linking moiety, while the... Agent: Olson & Hierl, Ltd.

20070286826 - Nontoxic, non-endocrine disrupting, cytoprotective, uv-radiation resistant sunblock compositions: The disclosure also describes a method for creating a composition, comprising: a) preparing a water phase mixture with a base of deionized water; b) optionally adding thickening or thinning agents into a water phase and mixing until free from lumps; c) optionally adding carrageenan into the mixture and mixing until... Agent: Guerry Leonard Grune

20070286828 - Varnish composition based on a solvent exclusively of vegetable origin: A varnish composition for cosmetic or pharmaceutical use, comprising at least one solvent of plant origin.... Agent: Harness, Dickey & Pierce, P.L.C

20070286829 - Antiperspirant or deodorant compositions: The stability of antiperspirant or deodorant compositions comprising an aqueous solution of an antiperspirant or deodorant salt that has been thickened by a polyquaternium derivative of an hydroxycellulose and containing lypophylic organic material can be improved by employing a stabilising amount of propylene glycol, preferably selected in the range of... Agent: Unilever Intellectual Property Group

20070286833 - Multistage polymer composition and method of use: There is provided a multistage polymer that comprises (a) at least one soft polymer having glass transition temperature of 40° C. or lower, and (b) at least one hard polymer having glass transition temperature higher than 40° C., wherein the glass transition temperature of said hard polymer is at least... Agent: Rohm And Haas Company Patent Department

20070286837 - Hair care composition comprising an aminosilicone and a high viscosity silicone copolymer emulsion: Hair care composition comprising an aminosilicone having a viscosity of from about 1,000 centistokes to about 1,000,000 centistokes, and less than about 0.5% nitrogen by weight of the aminosilicone; a silicone copolymer emulsion with an internal phase viscosity of greater than about 120×106 centistokes, as measured at 25° C.; and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286836 - Removal of hair cosmetics from show animals: The formulation disclosed comprises of a suitable solvent at a level for removing the hair stiffeners and other hair-adhered chemicals (say, from about 70% to about 95% w/w); an emulsifier at a level effective to emulsify the removed chemicals (say, from about 5% to about 25% w/w); and, optionally, a... Agent: Mueller And Smith, Lpa Mueller-smith Building

20070286831 - Cosmetic product and method of applying a mascara composition: A cosmetic product includes a mascara composition and a treatment device, whereby the mascara composition is applied to the eyelashes by softening the mascara composition via heat. The mascara composition is solid at room temperature, however is softened at elevated temperature, so it may be applied to the eyelashes. The... Agent: Kratz, Quintos & Hanson, LLP

20070286839 - Composition comprising jojoba carboxylates in combination with jojoba alcohol and cosmetic formulation comprising same: A non-aqueous mixture comprising a plurality of jojoba carboxylates in combination with a plurality of jojoba alcohols formed by saponifying jojoba oil. Furthermore, a variety of personal care formulations comprising a plurality of jojoba carboxylates in combination with a plurality of jojoba alcohols are disclosed.... Agent: Dale F. Regelman

20070286841 - Method for lowering serum glucose: n

20070286840 - Nitric oxide-releasing polymers: This invention relates to compositions comprising carbon-based diazeniumdiolates attached to hydrophobic polymers that releases nitric oxide (NO). The carbon-based diazeniumdiolated polymers release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated polymers, compositions comprising such polymers, methods of... Agent: Foley And Lardner LLP Suite 500

20070286842 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.... Agent: Novartis Corporate Intellectual Property

20070286843 - Recombinant polypeptides of the members of the tnf ligand family and use thereof: The invention relates to polypeptides comprising, as constituent A, at least three monomers of a member of the TNF ligand family and, as constituent B, at least two peptide linkers that link the monomers of the member of the TNF ligand family to one another. The invention also relates to... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070286844 - Storage and delivery of micro-organisms: A method of delivering a micro-organism to an animal, the method comprising providing a formulation comprising a micro-organism suspended in or on a matrix; providing a fee stream for the animal; detaching micro-organisms from the matrix; and entraining detached micro-organisms into the feed stream. An apparatus for delivering a micro-organism... Agent: Arent Fox LLP

20070286846 - Novel methods for ester detoxication: This invention relates to a method for detoxication of inorganic or organic esters including OP nerve agents, cocaine, and respective analogs. More specifically, this invention pertains to the treatment of potentially neurotoxic esters or other ester groups by elaborating a more effective hydrolytic enzyme for therapeutic application. The structures of... Agent: Jones Day

20070286845 - Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.... Agent: Martin D. Moynihan Prtsi, Inc.

20070286848 - Epas1 gene transfer to improve cell therapy: The present invention concerns the use of nucleotide sequences encoding EPAS1, HIF-1α and HIF-3α transcription factors and functional analogs for treating coronary and cardiac diseases in mammals. The use of such transcription factors and its analogs is useful in the treatment of disorders that may be treated by cell therapy... Agent: Sim & Mcburney

20070286847 - Adoptive immune cells for tumor vaccines: The present invention provides a method for preparing adoptive immune cells comprising the following steps of a) obtaining mammalian antigen-presenting associated cells; b) culturing the resulting cells in a culture vessel coated with a sugar chain-containing polymer; and c) detaching the cells by shaking the culture vessel without treating the... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070286849 - Treatment of autoimmune disorders: Disclosed herein are methods for the treatment of autoimmune or immune related diseases or disorders. Also disclosed are methods for treating such autoimmune or immune related diseases or disorders with the administration of expanded populations of regulatory T cells. Also disclosed herein are methods of treating autoimmune or immune related... Agent: Knobbe Martens Olson & Bear LLP

20070286850 - Mevalonate kinase: The present invention relates to modified mevalonate kinases that are less sensitive to feedback inhibition, and to polynucleotides encoding them. The invention further pertains to vectors comprising these polynucleotides and host cells containing such vectors. The invention provides a process for producing the modified enzyme and for producing isoprenoid compounds... Agent: Nixon & Vanderhye, PC

20070286851 - Method of identifying modulators of nogo-functions: Methods of treating acute neuronal injury by utilizing a BACE polypeptide that binds to Nogo, or compositions comprising such BACE polypeptide. Additional methods of treating a neoplastic, hyperproliferative or dysproliferative disorder, utilizing a BACE polypeptide that binds to Nogo, or compositions comprising such BACE polypeptide... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070286854 - Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1): The invention provides a human DPP1 which is associated with the infections, cardiovascular diseases, respiratory diseases, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, inflammation, hematological diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention... Agent: Banner & Witcoff, Ltd.

20070286853 - Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor delta (ppard): The invention provides a human PPARD which is associated with the cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of... Agent: Banner & Witcoff, Ltd.

20070286852 - Sppls as modifiers of the p53 pathway and methods of use: Human SPPL genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPPL are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070286855 - Improving treatments: Methods and materials for reducing a mammal's ability to produce antibodies against an antigen (e.g., a therapeutic polypeptide) to be administered to the mammal are provided herein.... Agent: Fish & Richardson P.C.

20070286857 - Anti-cd52 antibody treatment for diabetes: The present invention provides for the prevention and/or treatment of Type 1 diabetes mellitus with CD52 specific antibodies, e.g. CAMPATH-1H.... Agent: Fulbright & Jaworski L.L.P.

20070286859 - Fc variants having decreased affinity for fcyrl: The present invention relates to Fc variants having decreased affinity for FcγRI, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070286858 - Methods and compositions for antagonism of rage: Antibodies that bind specifically to receptor for advanced glycation end products (RAGE) and RAGE-binding fragments thereof are disclosed. Also disclosed are pharmaceutical compositions comprising such anti-RAGE antibodies and RAGE-binding antibody fragments thereof, and their use for treatment of RAGE related diseases.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070286856 - Modulation of hyaluronan synthesis and degradation in the treatment of disease: The present invention provides compositions and methods for modulating the expression of Hyaluronan (HA). In particular, this invention relates to compounds, which hybridize with nucleic acid molecules encoding hyaluronan synthase (HAS), particularly HAS isoforms HAS1, HAS2 and HAS3. These compounds may range in size from oligonucleotides to full length sequences.... Agent: Seed Intellectual Property Law Group PLLC

20070286860 - Compositions and methods for inducing anti-tumor immunity: Compositions and methods are provided for inducing anti-tumor immunity. More specifically, tumor cells and recombinant constructs are provided that express a cell surface CD83 polypeptide and/or a cell surface expressed antibody that specifically binds to an immune cell receptor, particularly an antibody that specifically binds to CD137. The invention also... Agent: Seed Intellectual Property Law Group PLLC

20070286861 - Immunoglobulins: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070286862 - Cancer associated antigens: The invention relates to isolated nucleic acid sequences which are expressed in cancers, especially gastrointestinal, kidney and prostate cancers, to their protein products and to the use of nucleic acid and protein products for the identification and treatment of cancers.... Agent: Barnes & Thornburg LLP

20070286863 - Cmklr regulation of adipogenesis and adipocyte metabolic function: Methods are provided for regulating adipogenesis and metabolic function in adipocytes by modulating the activity of chemokine-like receptor 1 (CMKLR1). Exemplary agents include those that modulate binding of CMKLR1 to a cognate ligand (e.g., chemerin), those that modulate signaling from CMKLR1, and those that modulate expression of either CMKLR1 or... Agent: Bozicevic, Field & Francis LLP

20070286864 - Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein... Agent: Osi Pharmaceuticals, Inc.

20070286865 - Use of he4 and other biochemical markers for assessment of ovarian cancers: The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.... Agent: Duane Morris, LLPIPDepartment

20070286866 - Compositions for reducing bacterial carriage and cnc invasion and methods of using same: Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneuomococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of either neuraminidase, phosphocholine, pneumococcal teichoic... Agent: Fish & Richardson P.C.

20070286867 - Combination therapy: The invention provides combination therapies and methods for the treatment of cancers associates with p53 mutations. The method comprises the separate, sequential or simultaneous administration of a therapeutically effective amount of a) a specific binding member, for example CH-11, which binds to a cell death receptor, for example Fas, or... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070286868 - Phosphorylcholine conjugates and corresponding antibodies: IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure>95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less... Agent: Fulbright & Jaworski L.L.P.

20070286869 - Influenza virus vaccine composition and methods of use: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070286870 - Modified vp1-capsid protein of parvovirus b19: The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.... Agent: Fulbright & Jaworski L.L.P.

20070286871 - Vaccines: The present invention relates to compositions for inducing immune responses, including an antigen and a promiscuous T-cell epitope. Also provided are methods of inducing immune responses in hosts, comprising administering compositions comprising antigens and promiscuous T-cell epitopes to the host.... Agent: Knobbe Martens Olson & Bear LLP

20070286872 - Live attenuated nidovirus vaccines: The present invention is directed live, attenuated Nidovirus vaccines, and in a particular embodiment, to coronavirus vaccines. The vaccine comprises a viral genome encoding a replicase polyprotein having at least one proteinase cleavage site that exhibits reduced or no cleavage. Such viruses show reduced.... Agent: Fulbright & Jaworski L.L.P.

20070286873 - Recombinant influenza h5 hemagluttinin protein and nucleic acid coding therefor: The present invention provides an improved form of a nucleic acid encoding for the influenza hemagluttinin H5N1. The optimized gene sequence permits production via recombinant means, of the H5N1 HA protein for use in diagnostic assays and vaccines.... Agent: Fulbright & Jaworski L.L.P.

20070286874 - Recombinant attenuated clostridium organisms and vaccine: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070286875 - Oral liquid loratadine formulations and methods: An oral liquid formulation including an effective amount of loratadine, or a pharmaceutically acceptable salt or metabolite thereof; and a pharmaceutically acceptable carrier including a mono- or poly-hydroxy phenol component, a solubilizing agent and a chelating agent. Methods of preparing and administering such formulations are also included.... Agent: Winston & Strawn LLP Patent Department

20070286876 - Skin care compositions comprising low concentrations of skin treatment agents: Skin care compositions may comprise from about 0.001% to about 0.1% by weight of hexamidine and either or both of (i) from about 0.001% to about 10% by weight of zinc oxide, and/or (ii) from about 0.01% to about 10% by weight of niacinamide.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286877 - Multi-functional protective textiles and methods for decontamination: A reactive and adsorptive (i.e., multi-functional protective) textile and methods for constructing and using same which possess at least chemically reactive and biocidal properties. Nanoparticles from different classes such as metal oxides, metal hydroxides, metal hydrates and POMs are incorporated into elements which can be utilized in a wide variety... Agent: Keusey, Tutunjian & Bitetto, P.C.

20070286878 - Removable films for sanitizing substrates and methods of use thereof: Described herein are removable films for sanitizing substrates and methods of use thereof.... Agent: Gardner Groff Greenwald & Villanueva. PC

20070286880 - Inoculated spongiform scaffold for transplantation and tissue regeneration: A spongiform scaffold which comprises epithelial stem cells, and free of mesenchymal cells. A spongiform scaffold comprising precursor keratinocytes for use in a method of transplantion of the scaffold to an epithelial cell target site in a recipient, resulting in growth of said epithelial stem cells and the ingrowth of... Agent: Stemedica Cell Technologies, Inc

20070286881 - Method, composition and kit for treating degenerated disc disease and discogenic pain: A method, and a corresponding kit and a pharmaceutical composition, is effective for treating discogenic pain caused by a degenerated disc. The method includes injecting a neurotropic agent and polymeric carrier, such as a fibrin sealant, into the degenerated disc. The fibrin sealant injected into the disc includes fibrinogen and... Agent: Andrews Kurth LLP Intellectual Property Department

20070286884 - Implantable microbial cellulose materials for hard tissue repair and regeneration: This invention relates to polysaccharide materials and more particularly to microbial cellulose containing materials having suitable implantation properties for repair or replacement of hard tissue. The invention also relates to the use of the implantable microbial cellulose as a bone void filler and as a carrier vehicle for active agent... Agent: Foley And Lardner LLP Suite 500

20070286882 - Solvent systems for coating medical devices: The present invention discloses a method of modulating drug release from a coating on a medical device, a medical device including a coating formed thereby, and a method of using the medical device for treating, preventing or ameliorating a medical condition.... Agent: Squire, Sanders & Dempsey LLP

20070286883 - Structuring hydrogels: e

20070286885 - Elastin-based copolymers: A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.... Agent: Squire, Sanders & Dempsey LLP

20070286887 - Fine powder of amino acid and suspension thereof: Fine powders of a slightly soluble amino acid having an average particle size of 0.1 to 5 μm, may be obtained by wet milling the slightly soluble amino acid. These powders are useful for preparing suspensions in which the fine powder is uniformly and stably dispersed.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070286886 - Materials and methods for inducing apoptosis in adipocytes: The subject invention provides for materials and methods of using dietary calcium, calcium-containing products, dairy and antagonists of calcitrophic hormone activity for inducing apoptosis in adipocytes in order to reduce the number of adipocytes in an individual regulating body weight.... Agent: Venable LLP

20070286888 - Additive for feeds and feed containing the same: An additive for feeds is provided which is efficacious in preventing and ameliorating digestive disorders such as diarrhea occurring as the side effects of the administration of antibiotics and a feed containing same. More specifically, an additive for feeds which comprises (A) Lactobacillus equi cells and (B) cells of at... Agent: Sughrue Mion, PLLC

20070286889 - Weight management system for obese animals: A pet food product for promoting comprehensive weight management in companion animals. The pet food includes, on a dry matter basis, about 35 to about 70% by weight of a protein, about 4 to about 10% by weight of a fat, about 5 to about 25% by weight of a... Agent: Fulbright & Jaworski, LLP

20070286890 - Eyelash applicator and method: p

20070286893 - Lotioned wipe product comprising an anti-stick agent and a performance enhancing agent: An anti-stick agent and a performance enhancing agent that may be incorporated into an aqueous medium to assist in the prevention of soils and bodily exudates adhering to the skin. A substrate may be utilized to assist in delivering the anti-stick agent and the performance enhancing agent to the skin.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286894 - Lotioned wipe product to reduce adhesion of soils or exudates to the skin: An anti-stick agent that may be incorporated into an aqueous medium to assist in the prevention of soils and bodily exudates adhering to the skin. A substrate may be utilized to assist in delivering the anti-stick agent to the skin.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286892 - Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions include a combination of a carrier component and a bioactive component which acts to prevent or reduce post-poperative ileus. Such methods include administering a therapeutically effective amount of the composition directly to the serosal... Agent: Philip S. Johnson Johnson & Johnson

20070286891 - Tissue-adhesive materials: This invention related to a tissue-adhesive sheet comprising a homogeneous, preformed and cross-linked matrix formed from one or more polymers, and having at least one surface that, in use, is exposed, at least one of said one or more polymers being a synthetic polymer and having appendant functional groups of... Agent: Nixon Peabody LLP - Patent Group

20070286895 - Wound dressing: The invention provides for the use of an effective amount of silver in the manufacture of a wound dressing comprising an anionic polymer, which dressing, when applied to the wound, gives a controlled release of ionic silver into the wound fluid for the prevention of staining of the underlying tissue.... Agent: Bristol-myers Squibb Company

20070286898 - Intracellular drug delivery improving liposome: [Means for Resolution] A drug-containing liposome for use in the treatment with a liposome prepared by employing polyethylene glycol cholesteryl ether as a part of the liposome-forming agent and using said liposome-forming agent. It is possible to obtain excellent drug effect by further employing a polyethylene glycol diacylglycerol ester as... Agent: Sughrue Mion, PLLC

20070286897 - Liposomal formulations of anthracycline agents and cytidine analogs: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent... Agent: Morrison & Foerster LLP

20070286896 - Therapeutic or diagnostic drug for inflammatory disease comprising targeting liposome: There is provided targeting drug delivery system (DDS) nanoparticles that can be accumulated in target tissues such as inflammatory sites of inflammatory diseases and can thus be utilized in a therapeutic or diagnostic DDS for locally delivering drugs or genes to the affected parts. The present invention provides a pharmaceutical... Agent: Sughrue Mion, PLLC

20070286899 - Photo-composition for the treatment of joint diseases: A phyto-composition is described for the treatment of joint diseases that comprises: a) from 0.01% to 26% in weight of an extract of Curcuma longa (turmeric); b) from 30% to 80% in weight of an extract of Harpagophytum procumbens, (devil's claws); c) from 0.01% to 25% in weight of an... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070286900 - Low dose tablets of opioid analgesics and preparation process: The present invention relates to a sublingual tablet and to the method for the preparation thereof.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070286901 - Novel pharmaceutical formulation of cefixime for enhanced bioavailability: A chewable tablet comprising Cefixime having a mean particle size between 20 μ and 120 μ wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of... Agent: Merchant & Gould PC

20070286902 - Dosage forms comprising a short acting sedative-hypnotic or salt thereof: In certain embodiments the invention is directed to an oral solid pharmaceutical dosage form comprising: a first portion of a short acting sedative-hypnotic in an release immediate release component; and a second portion of the sedative-hypnotic in a delayed component, the delayed release component comprising (i) a unitary core comprising... Agent: Davidson, Davidson & Kappel, LLC

20070286903 - Composition and method for taste masking: The present invention relates to a taste-masked composition of an active pharmaceutical ingredient (API) for oral delivery and a related method for the preparation of the taste-masked composition comprising a granulated mixture of the active pharmaceutical ingredient, an insoluble matrix component, a film-forming agent, and a water soluble binder... Agent: Banner & Witcoff, Ltd.

20070286904 - Structured materials: The present invention relates to a structured material comprising: a hydrophilic particle such as a hydrophilic silica, a silicate, a dextrin, a starch, a mineral, sodium bicarbonate, a clay, a sugar, a polyol, a dried flavor/fragrance, a hydrocolloid, a protein, a cellulose, methylcellulose, hydroxypropyl methyl cellulose, a wheat flour, corn,... Agent: International Flavors & Fragrances Inc.

20070286906 - Dihydrobenzoquinone compounds: e

20070286905 - Method for the preparation of trans-or cis-diammoniumdichlorodihydroxoplatinum(iv) and the use thereof in the production of pharmaceutical active substances: The invention relates to a method for the preparation of trans- or cis-diammoniumdichlorodihydroxoplatinum(IV) and derivatives thereof. What is suggested is reacting trans- or cis-diammoniumdichloroplatinum(II) with a solution comprising >30% peroxide at temperatures below 30° C. and dissolving the product thus obtained in a mineral acid and subsequently precipitating with an... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20070286907 - Germicide composition: A method and composition for removing biofilm, disinfecting and inactivating endotoxin which generates a safe level of molecular iodine that is free of persulfate ions. The composition can be used in households, industry, on medical equipment and skin surfaces.... Agent: John Lezdey & Associates

20070286908 - Salt and soap compositions: New compositions including salt components and/or antioxidant-containing botanical extract components, such as bamboo leaf extracts, acai berry extracts, lotus leaf extracts, other antioxidant-containing botanical extracts and mixtures thereof, are provided. The present compositions effectively take advantage of the chemical make-ups and/or properties of these components to provide new and/or enhanced... Agent: Stout, Uxa, Buyan & Mullins LLP

20070286909 - Amino acid compositions: Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanine, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histidine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric... Agent: Klarquist Sparkman, LLP

20070286911 - Huperzia serrate (thunb.) trev. composition comprising compounded huperzine a and huperzine b and methods for preparing it: The invention is directed to the field of natural medicine, specifically to alkaloid extracts of Huperzia serrata (Thunb.) Trev. A Huperzia serrata (Thunb.) Trev. composition and the method for preparing it are provided. The Huperzia serrata (Thunb.) Trev. composition comprises Huperzine A and Huperzine B, wherein the total content of... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070286910 - Method and composition for administering bioactive compounds derived from morinda citrifolia: This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant Morinda cirtrifolia to individuals. This invention relates to using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf. More particularly this... Agent: Kirton And Mcconkie

20070286912 - Method for promoting eye health: The present invention relates to a method for promoting eye health by administering to a companion animal a composition comprising at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070286913 - Animal food supplement compositions and methods of use: An animal food supplement particularly useful in treating gastrointestinal problems, such as colic. Psyllium husks are provided in dry form for convenience of handling prior to feeding. In examples of embodiments, psyllium husks are admixed with binding material and the admixture is formed into pellets, crumbles, mashes, or licks. Upon... Agent: Trask Britt

20070286914 - High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity: A complex, water soluble polysaccharide fraction having potent immunostimulatory activity isolated from Aloe vera. The polysaccharide fraction has an apparent molecular weight above 2 million daltons. Its major glycosyl components are glucose, galactose, mannose and arabinose. The invention further includes pharmaceutical compositions containing the instant polysaccharide fraction, optionally in combination... Agent: Hunton & Williams/new York Intellectual Property Dept.

20070286915 - Nerve growth factor production inhibitor and external preparation for the skin, cosmetic, quasi drug, preventive and remedy for atopic dermatitis containing the nerve growth factor production inhibitor: It is an object of the present invention to provide a nerve growth factor production inhibitor having a function to inhibit the production of the nerve growth factor deeply involved with the extension of C fiber to epidermis, as well as a high safety, and an external preparation for the... Agent: The Webb Law Firm, P.C.

20070286916 - Synbiotic use: The invention relates to the use of at least two lactic acid bacterial strains selected from the group comprising Pediococcus pentosaceus 16:1 (LMG P-20608), Leuconostoc mesenteroides 23-77:1 (LMG P-20607), Lactobacillus paracasei subsp paracasei F-19 (LMG P-17806), and Lactobacillus plantarum 2362 (LMG P-20606) for the manufacturing of a formulation for the... Agent: Merchant & Gould PC

20070280880 - Method for cell-specific targeting: Method for selective targeting of one or more effector moiety such as diagnostic or a therapeutic agent to a cell or population of cells expressing a folate-receptor comprising simultaneous or sequential administration of an antifolate with a folate- or pteroate-conjugate comprising said one or more effector moiety.... Agent: Millen, White, Zelano & Branigan, P.C.

20070280887 - System and methods for evaluating efficacy of appetite-affecting drugs: System and methods to evaluate and administer drugs. The present invention instantaneously identifies the effects that drugs, including appetite-affecting agents, have on animals. Data is collected automatically and analyzed and further organized to identify feeding patterns and the effect an appetite-affecting agent has on those feeding patterns. The present invention... Agent: Valauskas & Pine LLC

20070280890 - System and method for disinfecting and drying a surface: Disinfectant systems and methods of disinfecting a surface for drying are disclosed. One system comprises a carrier for drying the surface and an anti-microbial component for disinfecting the surface. The ant-microbial component forms a film-free coating containing an organic halogen salt when the carrier evaporates from the surface.... Agent: Brinks Hofer Gilson & Lione

20070280893 - Antibacterial composition to be used as a toothpaste for sanitating the oral cavity: An antibacterial composition to be used as a toothpaste for sanitating the oral cavity comprises an emulsion including an aqueous phase, in which water soluble antibacterial substances are dissolved, a powder phase and a third oil phase.... Agent: Hedman & Costigan P.C.

20070280894 - Cohesive emulsion composition comprising a bleaching agent: The present invention relates to a cohesive emulsion comprising a bleaching agent, an emulsifying system, an aqueous phase and an inert hydrophobic phase, wherein the hydrophobic (e.g. oil) phase is in predominant proportion relative to the aqueous phase. In one embodiment the invention relates to a delivery system for delivering... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070280896 - Use of non-hydroxide bases with heat for relaxing or straightening hair: A process for straightening or relaxing hair involving the steps of: (a) providing a hair straightening/relaxing composition containing: (i) from about 0.1 to about 50% by weight of at least one weak non-hydroxide base; and(ii) remainder, to 100%, a cosmetically acceptable medium, all weights based on the weight of the... Agent: L'oreal Usa/ Patent Department

20070280898 - Dermatological compositions: Embodiments of the present disclosure include a dermatological composition for the treatment of skin blemishes, more particularly for the treatment of scars and/or stretch marks. The dermatological composition can include 0.1-1.0 parts by weight of bulbus allium (onion) powder, 0.5-5.0 parts by weight of the obroma cacao (cocoa) seed butter,... Agent: Brooks, Cameron & Huebsch , PLLC

20070280902 - Method for treating eye disease or conditions affecting the posterior segment of the eye: This invention relates to the use of prodrug for the manufacture of a medicament useful for treating an ocular disease affecting the posterior segment of the eye, in a subject in need thereof, wherein the prodrug is a composition injected into the vitreous body, and the frequency of injections does... Agent: Young & Thompson

20070280905 - Prognosis and systemic therapy for treating malignancy: It has been discovered that a sequential administration by intramuscular electroporation of the gene for IL12 followed about 10 days later by the gene for IL27 eradicated tumors in 33% of mice with aggressive 4T1 breast malignancy. In addition, the mice in which the initial tumor was eradicated rejected subsequent... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20070280906 - Method to generate mirrored adenoassociated viral vectors: The present invention describes mirrored adenoassociated virus genomes that can spontaneously fold to form double-stranded DNA structures capable of directing efficient RNA transcription in mammalian cell nuclei. Also described are mirrored adenoassociated viral particles that incorporate the mirrored vector genome and a suitable adenoassociated viral capsid. Further described are DNA... Agent: Ognjen Petras

20070280914 - Method and use of a lactic acid bacteria with increased acid tolerance: The invention provides certain plasmid cured strains of lactic acid bacteria modified for their capability of better acid-tolerance, a method of modifying such strains, and products containing such strains.... Agent: Lynn E Barber

20070280922 - Combinations of human proteins to enhance viability of stem cells and progenitor cells: Embodiments of the present invention include the use of a composition of placental alkaline phosphatase or other members of the alkaline phosphatase family alone, or in combination with human transferrin and, optionally, human α1-antitrypsin to enhance the in vitro proliferation and survival of adult or embryonic stem cells and/or progenitor... Agent: Faegre & Benson LLP Patent Docketing

20070280923 - Recombinant fusion-enzyme with repair activity on dna lesions produced by uv radiation; its usage, preparation and purification method; a method to stabilize enzymes and treatment methods: A recombinant fusion enzyme repairs DNA damaged by UV radiation, and the method of preparing recombinant fusion enzyme. The method includes the fusion of an enzyme coded by a gene isolated from Micrococcus luteus and a stabilizing peptide having the amino acid sequence described in SEQ ID No 2. A... Agent: Lackenbach Siegel, LLP

20070280926 - Sting kit apparatus and method of use: A sting kit apparatus and method of use. The apparatus is a portable kit that can be easily transported to a beach and can be used to immediately treat jelly fish stings or stings from other stinging organisms such as bees, wasps, hornets, etc. The kit includes a solution including... Agent: Lesavich High-tech Law Group, P.C.

20070280879 - Therapeutic use of rm1 antigen: The antigen recognized by RM1 antibody is used for therapy, diagnosis and imaging.... Agent: Wilson Sonsini Goodrich & Rosati

20070280882 - Engineered anti-cd20 antibody fragments for in vivo targeting and therapeutics: The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.... Agent: Perkins Coie LLP

20070280881 - Tag-72 specific ch2 domain deleted antibodies: Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for... Agent: Pillsbury Winthrop Shaw Pittman, LLP Eric S. Cherry - Docketing Supervisor

20070280883 - Methods for carbon isotope labeling synthesis of ketones and amines by suzuki coupling reactions using carbon-isotope monoxide: Methods and reagents for synthesizing carbon-isotope labeled ketones and amines by carbonylation via Suzuki coupling reaction using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled ketones and amines are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided.... Agent: Ge Healthcare, Inc.

20070280884 - Insect poison allergens with reduced ige reactivity and method for producing the same: The invention relates to recombinant insect poison allergens and to a specific method for producing them. Said allergens can be varied according to whether they are produced using folds (conformations) that are identical or different to those that occur naturally. The proteins with folds that do not occur naturally have... Agent: Millen, White, Zelano & Branigan, P.C.

20070280886 - Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr): The invention provides a human AMDR which is associated with the cardiovascular diseases, infections, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or... Agent: Banner & Witcoff, Ltd.

20070280885 - Methods of treating demyelinating disorders: Methods of identifying and using compounds capable of treating demyelinating disorders such as multiple sclerosis by inhibiting EphB1-mediated cell repulsion of CNS and PNS glial cells (oligodendrocytes and Schwann cells and progenitor cells within these lineages).... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070280889 - Contrast agent system for x-ray imaging: A contrast agent system for X-ray and computed tomography diagnostics has a dissolvable microcapsule in which a substance or substance mixture that releases CO2 upon contact with a bodily fluid is enclosed.... Agent: Schiff Hardin, LLP Patent Department

20070280888 - Dental-plaque detection system and dental-plaque detection method: A dental-plaque detection system and dental-plaque detection method which are excellent in the detection accuracy of dental plaques and also capable of improving the situation to stain sites other than dental plaques (such as interdental parts and gums) are provided. The dental-plaque detection system includes a dental-plaque staining agent, which... Agent: Merchant & Gould PC

20070280891 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes a polyethylene glycol (PEG) or PEG derivative and mixtures thereof, wherein the PEG or PEG derivative is present at a... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070280892 - Mixture with wintergreen odor and flavor: The invention relates to a mixture of compounds having the sensory properties of winter-green, to fragrance and flavoring compositions containing said mixture and to flavored and perfumed products containing said mixture, to a method of adding a wintergreen flavor, odor or note to (non-wintergreen) flavored or perfumed products. Further the... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070280895 - Coated particles and sunscreen and cosmetic products containing same: Particles have an ultrathin, conformal coating are made using atomic layer deposition methods. The base particles include ceramic and metallic materials. The coatings can also be ceramic or metal materials that can be deposited in a binary reaction sequence. The coated particles are useful as fillers for electronic packaging applications,... Agent: Gary C. Cohn, PLLC

20070280897 - Cosmetic bases and cosmetics containing the same: (where Z represents a residue of a compound having 3 to 9 hydroxyl groups with the hydroxyl groups removed, a is from 3 to 9, AO represents an oxyalkylene group of 3 to 4 carbon atoms, EO represents oxyethylene group, l and m represent average additional mol numbers of the... Agent: Oliff & Berridge, PLC

20070280899 - Polyhydroxyalkanoates for in vivo applications: Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070280900 - Compositions having a high antiviral efficacy: Antiviral compositions having a rapid antiviral effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) a powdered solid substrate and (b) an organic acid.... Agent: Marshall, Gerstein & Borun LLP (dial)

20070280901 - Method of inhibiting the transmission of influenza virus: Antimicrobial compositions having a rapid and persistent antiviral effectiveness against influenza viruses, including avian flu viruses, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, and (c) water, wherein the composition has a pH of about 5 or less and the nonvolatile components of the... Agent: Marshall, Gerstein & Borun LLP (dial)

20070280903 - T1 receptor-like ligand ii and uses thereof: The present invention relates to a novel T1 Receptor (T1R)-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same. This invention further relates to... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070280904 - Lectin-derived progenitor cell preservation factors and methods of use: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070280907 - Adult bone marrow cell transplantation to testes creation of transdifferentiated testes germ cells, leydig cells and sertoli cells: This invention pertains to the discovery that stem cells (e.g., bone marrow stem cells) transplanted directly into a testicular environment are transdifferentiated into bona fide Sertoli cells, and/or Leydig cells, and/or and germ cells. This provides a mechanism for the treatment of male infertility and/or testosterone deficiency. Thus, in one... Agent: Beyer Weaver LLP

20070280910 - Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions: A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully... Agent: Intellectual Property / Technology Law

20070280909 - Shelf-stable product with living micro-organisms: The present invention relates to shelf-stable liquid products, for example diary products, comprising micro-organisms, especially probiotics. The micro-organisms are able to survive for several months at room temperature basically due to their inability to metabolise nutrients contained in the liquid product. The invention further relates to a method for manufacturing... Agent: Bell, Boyd & Lloyd LLP

20070280911 - Treatment of autism using probiotic composition: A method of treating autism using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions... Agent: Intellectual Property / Technology Law

20070280912 - Treatment of irritable bowel syndrome using probiotic composition: A method of treating irritable bowel syndrome using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet.... Agent: Intellectual Property / Technology Law

20070280913 - Use of selected lactic acid bacteria for reducing infantile colic: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.... Agent: Lynn E Barber

20070280908 - Treatment of diabetes with synthetic beta cells: Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose... Agent: Quarles & Brady LLP

20070280915 - Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound: The present invention provides pharmaceutical compositions comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound and methods for using the pharmaceutical compositions for reducing the risk of cardiovascular and other diseases.... Agent: Merchant & Gould PC

20070280916 - Pharmaceutical formulations comprising paraoxonase: The present invention provides a pharmaceutical formulation comprising paraoxonase (PON), a purification and stabilization method of PON, and an agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction containing PON as an active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070280917 - Susceptibility gene for myocardial infarction, stroke, and paod; methods of treatment: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD,... Agent: Marshall, Gerstein & Borun LLP

20070280918 - Multitherapy against cancer: The invention concerns a pharmaceutical composition for treating cancer characterized in that it comprises a combination of a PP2A methylating agent and an active principle selected among the group consisting of a phosphatase PP1 inhibitor, a histone diacetylase inhibitor, a direct or indirect pyruvate kinase activator, a PTEN agonist, a... Agent: Hunton & Williams LLP Intellectual Property Department

20070280919 - Produce-treatment composition and method for treatment of fresh produce: A produce-treatment composition is provided. According to an embodiment, the composition contains a nonionic surfactant, an antimicrobial agent, and a botanical extract from a plant selected from the Liliaceae and Cactus families, the extract retaining active enzymes and amino acids of the plant. Methods of treating produce and produce-handing and... Agent: Berenato, White & Stavish, LLC

20070280920 - Pharmaceutical composition comprising a factor viia and a factor xiii: The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department

20070280921 - Enzymatic synthesis, modification and degradation of silicon(iv)-and other metal(iv)-compounds: The present invention relates to the use of recombinant silicatein-β or silicatein-β isolated from natural sources as well as to silicatein-β-fusion proteins as well as silicatein-β-related enzymes for the synthesis, the degradation and for modification of silicon dioxide (condensation products of silicic acid, silicates), silicones and other silicon(IV)- or metal(IV)-compounds,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070280925 - Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases: This invention provides various combinations of enzyme replacement therapy, gene therapy, and small molecule therapy for the treatment of lysosomal storage diseases.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070280924 - Pharmaceutical preparations for and treatment of ocular surface and other disorders: A pharmaceutical preparation suitable for use in the eye, which comprises: (i) a pharmaceutically acceptable carrier suitable for use in the eye; (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial... Agent: Leon R. Yankwich Yankwich & Associates

20070280929 - Adjuvant in the form of a lipid-modified nucleic acid: The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally... Agent: Connolly Bove Lodge & Hutz LLP

20070280928 - Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors: The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the... Agent: Osi Pharmaceuticals, Inc.

20070280927 - Treatment of neurodegenerative diseases by the use of atp7a: The invention relates to the use of a ATP7A-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby the ATP7A-interacting molecule is preferably an inhibitor of ATP7A and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the... Agent: Clark & Elbing LLP

20070280933 - Methods for decreasing immune response and treating immune conditions: The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which... Agent: Biotechnology Law Group C/o Portfolioip

20070280935 - Antibody that recognizes phosphorylated peptides: The present invention relates to an antibody which recognizes an epitope consisting of Ser-Ile-A1-A2-A3- A4-Ser(PO3H2)-Pro-Gln-Leu-Ala-Thr-Leu-Ala-A5 (SEQ ID NO: 9), and does not bind to an epitope consisting of Ser-Ile-A1-A2-A3- A4-Ser-Pro-Gln-Leu-Ala-Thr-Leu-Ala- A5 (SEQ ID NO: 8), wherein A1 is Asp or Asn, A2 is Met or Leu, A3 is Val or... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070280931 - Antibody variants: Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.... Agent: Genentech, Inc.

20070280930 - Cd44-targeting for reducing/preventing ischemia-reperfusion-injury: The present invention relates to CD44 binding molecules, preferably anti-CD44 antibodies, and their use in methods for the prevention or reduction of ischemia-reperfusion injury in e.g. solid organ transplantation or in patients in shock. The invention further relates to methods wherein levels of soluble CD44 are determined in e.g. serum... Agent: Morgan Lewis & Bockius LLP

20070280934 - Compositions and methods for treating cocaine-related disorders: Methods for treating a cocaine-related disorder in an individual include administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In another embodiment, the light chain includes a human kappa light chain at least partially derived from... Agent: Dinsmore & Shohl, LLP

20070280932 - Tumour necrosis factor binding ligands: The present invention relates to ligands that bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of... Agent: Morrison & Foerster LLP

20070280936 - Method for treating psoriasis: A method for treating psoriasis. An antagonist to IL-17Dβ9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17Dβ9 or its receptor or a soluble receptor that binds to IL-17Dβ9 or a membrane-spanning protein-5 (MSP-5).... Agent: Zymogenetics, Inc. Intellectual Property Department

20070280937 - Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases: Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are provided. In particular, the detection, prevention and treatment of infectious diseases and cancer mediated and/or indicated by the presence and co-localization of a... Agent: Medlen & Carroll, LLP

20070280938 - Peptides derived from natural cytotoxicity receptors and methods of use thereof: The present invention relates in general to specific NCR-derived peptides capable of binding to membrane-associated biomolecules of the tumor cells, said biomolecules comprising at least one sulfated polysaccharide. Preferred peptides are about 7 to about 120 amino acids in length and are derived from NKp-44, NKp30 or NKp46.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070280939 - Prostatic acid phosphatase antigens: The invention relates to peptides from Prostatic Acid Phosphatase (PAP), especially those identified as PAP.135 and PAP.161. The nucleic acid molecules encoding the peptides, antibodies against the peptides, and the use of such peptides, nucleic acids and antibodies in immunotherapy, vaccines and assays are also included in the scope of... Agent: Barnes & Thornburg LLP

20070280940 - Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death: The present invention is directed to compositions and methods for treating cerebral edema and cell death in neurological conditions characterized by disruption of the architecture of the neurovascular unit with increase in the permeability of the NVU, particularly for treating stroke. One aspect of the present invention relates to a... Agent: Dla Piper US LLP Attn: Patent Group

20070280941 - Vcam-1 specific monoclonal antibody: The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis... Agent: Joseph Hyosuk Kim Jhk Law

20070280943 - Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases: The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.... Agent: Fish & Richardson PC

20070280942 - Compositions and methods for modulating immune responses: The present invention provides a newly identified CD28 family member that functions as lymphocyte inhibitory receptor termed pG6b, which is expressed on T cells. Methods and compositions for modulating pG6b-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic, and research purposes are also provided.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070280945 - High affinity antibodies to human il-6 receptor: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at... Agent: Regeneron Pharmaceuticals, Inc

20070280944 - Use of 5,10-methylene tetrahydrofolate for the treatment of cancer: The present invention provides novel uses and compositions for 5,10-methylene tetrahydrofolate (“5,10-CH2-THFA”) in the treatment of cancer. The present invention is based on the surprising result that 5,10-CH2-THFA, while increasing the efficacy of 5-fluoruracil (5-FU) in reducing the rate of tumor growth and increasing survivorship, also reduces the toxicity to... Agent: Townsend And Townsend And Crew, LLP

20070280946 - Antibody to 5' -deoxy-5' - methylthioadenosine and uses thereof: The present invention provides a new immunogen, a novel antibody having high specificity for MTA (5′-deoxy-5′-methylthioadenosine), methods of treatment and medicaments prepared using said antibody, and sensitive assays for measuring spermidine synthase activity.... Agent: John P. White Cooper & Dunham LLP

20070280947 - Tie receptor and tie ligand materials and methods for modulating female fertility: The present invention provides materials and methods involving Tie receptors and Angiopoietin ligands for modulating female fertility in mammals, including humans. Materials and methods for inhibiting fertility (e.g., for contraception) or for enhancing fertility (e.g., treating infertility) are contemplated.... Agent: Marshall, Gerstein & Borun LLP

20070280948 - Mammary stem cell marker: It is disclosed here that low density lipoprotein receptor-related protein 5 (LRP5) is a cell surface marker for somatic mammary stem cells and mammary tumor stem cells. The disclosure here provides new tools for enriching somatic mammary stem cells and mammary tumor stem cells. Methods of screening for agents that... Agent: Quarles & Brady LLP

20070280949 - Combination therapy for gastroenteric diseases caused by microorganisms: The manufacture of a pharmaceutical composition comprising egg yolk antibodies and at least one probiotic and the use thereof to treat diseases caused by enteric pathogens is described.... Agent: Ade & Company

20070280950 - Inflammatory cytokine inhibitors: A search was conducted for functional antibodies that endogenously regulate cytokines, focusing on the relationship between inflammatory diseases and cytokines. Mice were immunized with a human peripheral blood monocyte fraction and the obtained antibodies were examined for a cytokine-regulating effect. As a result, of these antibodies, antibody #33 was confirmed... Agent: Townsend And Townsend And Crew, LLP

20070280951 - Cell death inducing agents: The present inventors constructed a DNA expression vector encoding 2D7sc(Fv)2 in which the heavy chain variable region sequence (VH) and the light chain variable region sequence (VL) of the 2D7 antibody is arranged in the order of VH-VL-VH-VL, and these sequences are linked by a 15-mer linker. The vector was... Agent: Fish & Richardson PC

20070280952 - Modified reoviral therapy: The present invention relates to hyperproliferative diseases. Specifically, the present invention encompasses pharmaceutical compositions comprising a modified Reoviridae virus, wherein the Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance of the composition and reduce the immunogenicity of the composition. Yet further, the... Agent: Fulbright & Jaworski, LLP

20070280953 - Amyloid beta gene vaccines: The invention generally concerns compositions and methods for genetic vaccination with amyloid beta (Aβ) protein. Such vaccines may provide effective treatment for neurodegenerative disease such as Alzheimer's disease. Vaccination methods are can be used to induce a Th2 type immune response directed to Aβ. This immune response id shown to... Agent: Fulbright & Jaworski L.L.P.

20070280954 - Novel immunomodulating peptide: Epitopic fragments of Nogo, including Nogo 45-66, elicit a specific and strong T cell response, and a B cell response. T cells reactive to Nogo antigens are capable of ameliorating ongoing disease, which may be induced with other antigens. The present invention provides compositions and methods for the identification and... Agent: Townsend And Townsend And Crew, LLP

20070280955 - Novel virulence determinant within the e2 structural glycoprotein of classical swine fever virus: Classical Swine Fever Virus (CSFV) E2 glycoprotein is a major inducer of neutralizing antibodies and protective immunity in swine. E2 mediates virus adsorption to the target cell, and harbors genetic determinants associated with virus virulence. CSFV E2 also contains between residues 829 and 837 a discrete epitope (TAVSPTTLR) recognized by... Agent: Usda, Ars, Ott

20070280956 - Novel hepatitis c virus peptides and uses thereof: Novel hepatitis C virus (HCV) polypeptides are provided which are not encoded by the standard HCV open reading frame. These alternate reading frame polypeptides are useful, inter alia, in vaccine compositions, in diagnosing HCV infection, and as therapeutic targets.... Agent: Lahive & Cockfield, LLP

20070280957 - Change of the load state of mhc molecules: The present invention relates to methods for changing the load state of MHC molecules with ligands, the change in the load state being catalysed by a compound of formulae I, IA, II, III or IV1 to IV3. The invention relates further to the use of compounds of formulae I, IA,... Agent: Klauber & Jackson

20070280958 - Therapeutic uses of chemokine variants: Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070280959 - Use of platelets or platelet rich plasma(prp): A new use is disclosed for the content of platelets or platelet rich plasma (PRP) obtained by disruption of their membranes for the preparation of an agent for the treatment of bone, cartilage or skin.... Agent: Jones Day

20070280960 - Recombinant vaccine against bluetongue virus: n

20070280961 - Cdna corresponding to the antigenome of nonsegmented negative strand rna viruses and process for the production of such viruses: The present invention relates, in general, to a methodology or the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable... Agent: Trask Britt

20070280962 - Hbv core antigen particles with multiple immunogenic components attached via peptid ligands: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070280963 - Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus and the cells used in this method, the corresponding generic tools, as well as the applications of these non-pathogenic amplicon vectors: Improved methods for making non-cytotoxic helper virus-free preparations of herpes virus amplicon vectors or particles, the vectors themselves, recombinant helper virus and cells and methods of using same to treat patients and as tools in therapy and prevention, immunology, molecular biology, biotechnology and genetic engineering. In one embodiment, an amplicon... Agent: James C. Lydon

20070280964 - Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic fhv-1 infections, and preventing or treating conjunctivitis: Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and/or preventing or treating conjunctivitis in animals. The compositions contain effective amounts of probiotic Enterococcus bacteria and the methods involve administering such compositions to animals alone, in supplements, or in food compositions in... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources, Inc.

20070280965 - Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and... Agent: Allergan, Inc.

20070280966 - Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and... Agent: Allergan, Inc.

20070280967 - Cryo-protective agents for microorganisms: A lyophilization medium fora microorganism is provided wherein the medium is substantiality free of animal-derived products and comprises yeast extract and monosodium glutamate. The lyophilisation medium can be used for cryoprotection of strains of bacteria such as Corynebacterium diphtheriae. Method for preparing a freeze-dried culture of a microorganism using the... Agent: Reza, Yacoob, Sanfoi, Pasteur Limited

20070280968 - Live attenuated bacterial vaccine: A live, attenuated bacterium of the genus Escherichia, Yersinia or Salmonella, that does not have a functional tRNA5leu, and vaccines comprising the live, attenuated bacterium.... Agent: Intervet Inc. Patent Department

20070280969 - Rsf-1 as a prognostic marker and therapeutic target: The instant invention provides cancer markers and methods of prognosis and diagnosis based on detection and/or quantitation of these markers. The invention further provides compositions for the treatment of cancer.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20070280970 - Methods of treating wounds with gonyautoxins: Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission which are useful in treating anal fissure and other wounds and muscle disorders are provided. Also provided are methods of treating wounds and muscle disorders by administering the composition of the invention to a muscle or in the... Agent: Knoble, Yoshida & Dunleavy

20070280972 - Adhesive solid gel-forming formulations for dermal drug delivery: The present invention is drawn to adhesive solid gel-forming formulations, methods of drug delivery, and solidified gel layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a gelling agent. The solvent vehicle can include a volatile solvent system having one or more... Agent: Thorpe North & Western, LLP.

20070280973 - Composite material and method of producing a composite material of this type: To refine composite materials, the present invention suggests a composite material made of at least three layers, in which at least one of the layers has active ingredient, ceramic nanoparticles, silver salts, or nanoparticulate carbon modifications.... Agent: William Collard Collard & Roe, P.C.

20070280971 - Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor:

20070280976 - Multi-phased personal care composition comprising a blooming perfume composition: A multi-phase personal care composition is described comprising is a first phase and a second phase. The personal care composition comprises at least 0.25%, by weight of the composition, of blooming perfume ingredients having a KI of less than about 1500.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070280975 - Method for producing maca extract: The present invention provides an efficient extraction method of Maca extract having safe anti-allergic effects enabling long-term intake, and a food and beverage product, a perfumery and a cosmetic as well as a pharmaceutical preparation comprising thus obtained Maca extract showing anti-allergic effect. In the provided extraction method of Maca... Agent: Drinker Biddle & Reath (dc)

20070280977 - Multiple emulsion excipient for cosmetic actives: The present invention relates to a P/O/W-type multiple emulsion, constituted by two phases: an aqueous phase composed of an oil-in-water emulsion and an oil phase composed of a polvol-in-oil emulsion, wherein said oil phase comprises at least one lipophilic emulsifying agent, at least one lipophilic co-emulsifying agent and at least... Agent: Alston & Bird LLP

20070280979 - Solid oil-in-water emulsion: The present invention aims to provide solid compositions comprising an oil-in-water emulsion that have sufficient hardness and good feel when used, and can sufficiently exhibit the physiological functions of an electrolyte. A solid composition is obtained by preparing an oil-in-water emulsion by combining a solid oil (A), a liquid oil... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070280978 - Specular-gloss nail enamels: The present invention provides (a) a nail enamel characteristically containing noble metal colloidal particles having an average particle size of 10-100 nm whose concentration is 5-50 wt % of the total amount of the nail enamel. It also provides a 2-formula type nail enamel that is a combination of this... Agent: Townsend & Banta C/o Portfolio Ip

20070280974 - Temperature sensitive state-changing hydrogel composition and method for their preparation: The object of this invention is to provide a temperature-sensitive state-changing hydrogel composition and a method of producing the same. The hydrogel composition includes 1-10 wt % of branched gelation polymer, 0.5 5 wt % of electrolyte gelation polymer, 0.5-5 wt % of skin-communication enhancer, 1-10 wt % of natural... Agent: Wells St. John P.s.

20070280980 - Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic: A percutaneous pharmaceutical preparation for external use containing a nonsteroidal antiinflammatory analgesic. It is effective in inhibiting, with higher certainty, the hypersensitivity to light attributable to the phototoxicity and photoallergy of nonsteroidal antiinflammatory analgesics. It can sufficiently produce the effects of the nonsteroidal antiinflammatory analgesic while preventing the pharmaceutical preparation... Agent: Edwards Angell Palmer & Dodge LLP

20070280981 - Adherent biologically active ingredient carrier granule: A composition is provided that includes an inventive biologically active ingredient carrier granule that adheres to the surface of plants, grasses, and weeds using a moisture-active coating, illustratively including gum Arabic, guar gum, gum karaya, gum tragacanth and locust bean gum. Upon application of the inventive granule onto a plant... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070280982 - Antimicrobial compositions comprising hop acid alkali salts and uses thereof: The invention features anti-microbial compositions comprising compositions of hop acid alkali metal salts and alkaline earth metal salts and methods of using them to inhibit microbial growth.... Agent: Edwards Angell Palmer & Dodge LLP

20070280983 - Medical devices having improved performance: According to an aspect of the present invention, medical devices are provided that contain at least one polymeric region which contains (a) at least one block copolymer that contains at least at least three polymer blocks that differ from one another and (b) at least one therapeutic agent.... Agent: Mayer & Williams PC

20070280984 - Bioreactor: A process for producing a bioreactor using viable immobilized biological material. The process produces a siliceous layer capable of biomass immobilization and selectively cutting off of macromolecules having a molecular weight higher than a selected threshold. The process includes the steps of: (a) supplying a gas flow of a gas... Agent: Dickstein Shapiro LLP

20070280988 - Coating layers for medical devices and methods of making the same: Methods are disclosed for controlling the morphology and the release-rate of active agent from coating layers for medical devices comprising a polymer matrix and one or more active agents. The methods comprise fixing the morphology or phase distribution of the active agent prior to removing solvent from the coating composition.... Agent: Squire, Sanders & Dempsey LLP

20070280986 - Intra-operative coating of implants: Embodiments described herein provide methods and systems for applying biologically-active coatings to implants. More particularly, embodiments relate to methods for intra-operative coating of implants, such as orthopedic implants, with biologically-active coatings, such as coatings containing osteoinductive and osteoconductive biological components. An embodiment provides a method for applying a biologically-active coating... Agent: Hunton & Williams LLP Intellectual Property Department

20070280990 - Anti-adhesion barrier: The present disclosure relates to medical devices comprising at least a first film layer and at least a second gel layer and to methods for preparing such devices.... Agent: U.s. Surgical, A Division Of Tyco Healthcare Group

20070280987 - Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces: According to an aspect of the present invention, bioactive polymers are provided which have (a) a hydrophilic bioactive portion and (b) at least one hydrophobic polymer group that is linked to the hydrophilic bioactive portion by a covalent linkage that contains a chain transfer agent residue. According to another aspect... Agent: Mayer & Williams PC

20070280989 - Compositions and methods for stem cell expansion and differentiation: The present invention relates to compositions comprising stem cells and partially committed progenitor cells and to methods of controlling cell proliferation and differentiation, which can be used for expansion of stem cells and their subsequent differentiation. The present invention provides expanded population of essentially undifferentiated stem cells, which are useful... Agent: Fennemore Craig

20070280985 - Methods of establishing intercellular communication in an endothelial cell layer and uses thereof: The present invention provides methods for generating endothelial cells in vitro, with functional intercellular communication (e.g. GJIC) that is consistent with normal endothelial cells and cell layers in vivo. In accordance with the invention, expression and appropriate organization of gap junctional proteins in endothelial cells is achieved through a) biophysical... Agent: Elmore Patent Law Group, PC

20070280991 - Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug: Provided herein is a coating that includes cRGD for endothelial cells and methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20070280992 - Sustained delivery formulations of rapamycin compounds: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The... Agent: Schwegman, Lundberg & Woessner, P.A.

20070280994 - Ocular tissue separation areas with barrier regions for inlays or other refractive procedures: Ocular tissue separation areas having a barrier region are described herein. In one embodiment, the tissue separation area can have an implant placement site configured to accept an ocular implant. The barrier region can be located about at least a portion of the periphery of the implant placement site. The... Agent: Orrick, Herrington & Sutcliffe, LLPIPProsecution Department

20070280995 - Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye: Use of a composition comprising at least one prodrug of a steroid, preferably of a corticosteroid, for the preparation of an ophthalmic composition intended for the treatment of an ocular condition or disease of a human being or an animal.... Agent: Young & Thompson

20070280993 - Corneal epithelial sheet, method of constructing the same, and transplantation method using the sheet: A corneal epithelial sheet having potential for the achievement of a favorable therapeutic effect and being highly safe in transplantation. The corneal epithelial sheet is constructed by: (a) preparing corneal epithelial cells; (b) separately culturing human fibroblasts in a collagen gel; (c) sowing or placing the corneal epithelial cells on... Agent: Kratz, Quintos & Hanson, LLP

20070280997 - Composition for enhancing muscle recovery: An essential composition that acts to prevent or retard loss of muscle strength and atrophy during extended periods of inactivity is provided. The compositions are characterized by a ratio of carbohydrate to protein of from about 1.5:1 to 2:1 and by the presence of a specific amino acid component of... Agent: Gibbons P.C.

20070280998 - Dairy product: The present invention provides a novel feedstock and method of feeding dairy cows. Milk products derived from cows fed the feedstock are also encompassed. Milk comprising at least 0.3% DHA/g of fatty acids and food products containing components of that milk are also included. The milk product of the invention... Agent: Gowling, Lafleur Henderson LLP

20070280996 - Dietary supplement having improved efficacy at time of consumption: A dietary supplement that includes a container having a first compartment and a second compartment. The first compartment includes an aqueous medium. The second compartment includes an ingredient that is stable when stored within the second compartment. The container is configured such that a user may selectively cause the first... Agent: Iovate Health Science Research Inc.

20070280999 - Orally administrable composition for the photoprotection of the skin: An orally administrable composition for the photoprotection of the skin which comprises the combination of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.... Agent: Bell, Boyd & Lloyd LLP

20070281000 - Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof: The present invention provides stable pharmaceutical compositions comprising moisture sensitive drugs, in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, as the active ingredient, and at least one pharmaceutical excipient, wherein the active pharmaceutical ingredient is wet granulated with a solution of at least one pharmaceutical excipient, and... Agent: Kenyon & Kenyon LLP

20070281001 - Cat in heat cool formula™: An added vitamins that is found in PURINA CAT CHOW® and KNO3 to animal food products is to provided a natural and safe formula for cats and other animals having heat cycles, due to hormones changes that need cooling by a male or by surgical sterilization, known as spading. This... Agent: Herman Douglas

20070281002 - Low irritation antimicrobial cleaning substrate: The transfer of antimicrobial agent from a cleaning substrate to the skin can be reduced resulting in reduced skin irritancy when the viscosity of the cleaning composition containing the antimicrobial is increased in viscosity. The transfer is measured by the Simulated Hand Transfer Method. The cleaning substrate is used to... Agent: The Clorox Company

20070281003 - Polymer-based films and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component... Agent: Hoffmann & Baron, LLP

20070281004 - Polymeric film: A polymeric film comprising an alkylene oxide homo- or copolymer, wherein the film comprises a coherent pattern of cross-linked alkylene oxide homo- or copolymer and areas of non-crosslinked alkylene oxide homo- or copolymer, is useful as an adhesive film or for preparing an adhesive film.... Agent: Union Carbide Chemicals And Plastics Technology Corporation

20070281005 - Method of treating and diagnosing sleep disordered breathing and means for carrying out the method: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use... Agent: Dickstein Shapiro LLP

20070281006 - Methods and compositions comprising supramolecular constructs: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070281007 - Mucoadhesive oral formulations of high permeability, high solubility drugs: Solid oral dosage formulations, such as tablet, mini-tab, multiparticulates or osmotic delivery systems, are coated with a mucoadhesive polymeric coating or formed of a mucoadhesive polymer to increase oral bioavailability of Biopharmaceutical Classification System (BCS) Class I drugs. Representative BCS I drugs include valacyclovir, gabapentin, furosemide, levodopa, metformin, and ranitidine... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070281008 - Personal lubricant compositions and kits for providing personal lubrication: This invention relates to body orifice moisturizing compositions and kits and methods of their use. More particularly, it relates to vaginal moisturizing compositions and kits and methods of their use. The vaginal moisturizing compositions of this invention are preferably in the form of a soft gelatin capsule containing therein a... Agent: Philip S. Johnson Johnson & Johnson

20070281010 - Compositions and methods for enhancing brain function: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieve the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine... Agent: Fish & Associates, PC Robert D. Fish

20070281009 - N-acetylglucosamine tablet disintegrating in oral cavity and process for producing the same: It is intended to provide an N-acetylglucosamine tablet, with which N-acetylglucosamine can be taken in an amount at which a physiological activity can be expected in a small number of tablets, and which has an excellent disintegrating property and solubility in the oral cavity and has an adequate hardness to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070281011 - Nanoparticulate posaconazole formulations: The invention is directed to compositions comprising a nanoparticulate posaconazole, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate posaconazole particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of fungal infection and... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070281012 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070281015 - Anti-acid pharmaceutical composition in powder form and process for making it: An anti-acid pharmaceutical composition for the rapid and prolonged neutralization of gastric acidity with mucosa-protecting activity in powder form to prepare, by dispersion in water, a pharmaceutical solution or suspension for oral use characterized in that the composition includes sodium alginate; an anti-acid soluble agent or a combination of anti-acids;... Agent: Bachman & Lapointe, P.C.

20070281013 - Prednisolone salt formulations: The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.... Agent: Davidson, Davidson & Kappel, LLC

20070281014 - Prednisolone salt formulations: The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The tablets include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.... Agent: Davidson, Davidson & Kappel, LLC

20070281019 - Phenylephrine pulsed release formulations and pharmaceutical compositions: The invention discloses a pulsed-release formulation or a pharmaceutical composition comprising phenylephrine. The pharmaceutical composition comprises an immediate-release component and an enteric-coated component formulated together either in solid form or in a suspension. The enteric-coated component comprises microcrystals seeded with phenylephrine as an active ingredient and coated with a pH... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070281017 - Sustained release oxycodone composition with acrylic polymer and metal hydroxide: The invention is a controlled release composition comprising a therapeutic amount of an active ingredient in a controlled release matrix. The matrix comprises a combination of a pharmaceutically acceptable acrylic polymer and a metal hydroxide. The amount of metal hydroxide, relative to a given amount of acrylic polymer, is selected... Agent: Guy Donatiello Endo Pharmaceuticals

20070281016 - Sustained release oxycodone composition with acrylic polymer and surfactant: The invention is a controlled release composition comprising a therapeutic amount of an active ingredient in a controlled release matrix. The matrix comprises a combination of a pharmaceutically acceptable acrylic polymer and a metal hydroxide. The amount of surfactant, relative to a given amount of acrylic polymer, is selected for... Agent: Guy Donatiello Endo Pharmaceuticals

20070281020 - Pharmaceutical compositions for sustained release of phenylephrine: The invention discloses a pharmaceutical composition comprising phenylephrine in a sustained-release formulation alone or in combination with another active such as an antihistamine, an analgesic, an antipyretic or a non-steroidal anti-inflammatory agent or a mixture of two or more other actives. In a preferred embodiment, the composition comprises a solid... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070281021 - Sustained release formulation of naltrexone: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment.... Agent: Knobbe Martens Olson & Bear LLP

20070281018 - Sustained release formulations of opioid and nonopioid analgesics: The present invention relates to SRSR solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.... Agent: Dykema Gossett PLLC

20070281022 - Dosage forms having a microreliefed surface and methods and apparatus for their production: The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of... Agent: Philip S. Johnson Johnson & Johnson

20070281023 - Pharmaceutical composition for modified release insulin sensitiser: A pharmaceutical composition which composition comprises an insulin sensitiser and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitiser and the use of such composition in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070281024 - Two-piece, internal-channel osmotic delivery system flow modulator: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery... Agent: Dewipat Incorporated

20070281025 - Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal: Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount... Agent: Marshall, Gerstein & Borun LLP

20070281026 - Elastin stabilization of connective tissue: A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm... Agent: Dardi & Associates, PLLC US Bank Plaza

20070281027 - Multilaminate backing construction: A novel backing construction for a transdermal drug delivery system is disclosed. In particular, the invention relates to a system and method for labeling a transdermal drug delivery system, wherein the backing layer contains a writable medium capable of inkless printing.... Agent: Philip S. Johnson Johnson & Johnson

20070281029 - Method for preparing high absorbent hydrocolloid: The present invention relates to a method for preparing a hydrocolloid which may be applied to skin, particularly, wounds. The present invention comprises a first step of preparing a pre-polymer having a viscosity of 200 cps˜10,000 cps by mixing an acryl monomer and an ultraviolet initiator and irradiating on the... Agent: Cantor Colburn, LLP

20070281028 - Drug delivery of a cox inhibitor from embolic agents: A pharmaceutical composition for malignant tumour embolisation comprises a polymer and, associated with the polymer in a releasable form, a COX inhibitor, e.g. a non-steroidal anti inflammatory drug, such as ibuprofen. The polymer is preferably-in particulate form, such as in the form of microspheres. A suitable polymer is a crosslinked... Agent: Sughrue Mion, PLLC

20070281032 - Method for generating polymeric wear particles: In a method for generating polymeric wear particles for use in animal experiments as polymeric medical implant pre-clinical testing, microfabrication technique is used to design different mask patterns and obtain a uniformly sized and oriented microfabricated surface, which is used with a reciprocating wear tester to conduct an experiment on... Agent: Dykema Gossett, PLLC Suite 300 West

20070281031 - Microparticles and methods for production thereof: An active agent and a non-polymeric polyanionic compound are allowed to be associated with a microparticle containing an anionic macromolecule and an anionic polymer in the presence of a crosslink activator. In a non-limiting example, the non-polymeric polyanionic compound is a polyanionic amino acid such as aspartic acid or glutamic... Agent: Baxter Healthcare Corporation

20070281034 - Magnetic microparticles comprising organic substances: The invention provides for water-dispersible microparticles comprising magnetic material and organic substance, such as a pharmaceutical or a pigment, that constitute in totality at least 50%, or preferably more that 70%, of the dry mass of the particle. The method of making such microparticles is also provided, comprising coating of... Agent: Dmitri B. Kirpotin, Phd

20070281030 - Non-lamellar compositions of dope and p80: The present invention relates to particulate compositions comprising at least 50% of dioleoyl phosphatidyl ethanolamine (DOPE) and 1 to 50% of Polysorbate 80 (P80). All parts are by weight relative to the sum of the weights of a+b and the compositions comprise non-lamellar particles or form non-lamellar particles when contacted... Agent: Nixon & Vanderhye, PC

20070281033 - Skin exfoliation: The invention relates to a treatment composition for exfoliating skin comprising a particulate erasing agent, the particles of the erasing agent being dimensioned to roll along a surface. The particles have an average maximum diameter of between 30 and 1000 microns and consist of a precipitate of calcium carbonate. A... Agent: Wolf Greenfield & Sacks, P.C.

20070281035 - Release coating and process: A release coating having improved stability under aging conditions of heat and humidity is described whose release force can be altered by varying the amount of multi-lobe emulsion polymers relative to release agent.... Agent: Rohm And Haas Company Patent Department

20070281036 - System and method of delivering a desired material to a cell: The invention relates to compositions of mesoporous inorganic oxide particles and methods of use. The particles may be coated with a polyethylene glycol group. The compositions of the invention are useful for delivering therapeutic and diagnostic materials to an organism.... Agent: Wolf Greenfield & Sacks, P.C.

20070281037 - Sterile preparations and compositions including stinging capsules and methods of producing and using same: A sterile stinging capsule preparation and methods of producing and using same are provided.... Agent: Martin Moynihan C/o Anthony Castorina

20070281038 - Method of using a protein concentrate: A method for treating metabolic disorders or illnesses associated with metabolic disorders by administering a protein-rich nutrient concentrate as a dietetic food. Studies show that the administration of concentrate leads to highly significant normalization of numerous parameters that are considered to be risk factors or markers for cardiovascular illnesses and... Agent: William Collard Collard & Roe, P.C.

20070281039 - Essential oils based disinfecting compositions having tuberculocidal and fungicidal efficacies: The present invention provides disinfecting compositions having tuberculocidal and fungicidal efficacies for disinfecting and sanitizing inanimate surfaces. The disinfecting compositions contain thyme oil or thyme oil and origanum oil, a salt of a transition metal, a biobased surfactant and water. This improved disinfecting composition of the present invention is botanical,... Agent: Bereskin And Parr

20070281040 - Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents: The present invention relates to therapeutic combinations and methods of inhibiting the proliferation of cancerous cells, the abnormal growth of cells, and tumor cell growth using the combination of a hedgehog inhibitor with chemotherapy and/or radiation therapy. The present invention also relates to methods of enhancing the antiproliferative effect of... Agent: Michael Best & Friedrich LLP

20070281041 - Compositions and methods involving mda-7 for the treatment of cancer: The present invention concerns methods and compositions involving MDA-7 protein or an MDA-7-encoding nucleic acid and an EGFR inhibitor for the treatment of cancer. In certain embodiments, the invention specifically concerns a small molecule tyrosine kinase inhibitor, for example, erlotinib, as the EGFR inhibitor.... Agent: Fulbright & Jaworski L.L.P.

20070281042 - Combinations of chromium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070281043 - Microbicidal composition: A microbicidal composition comprising relatively high levels of a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one; a metal nitrate; and water. The composition optionally contains magnesium chloride.... Agent: Rohm And Haas Company Patent Department

20070281044 - Use of cold-pressed edible seed oils, flours, and/or blends thereof as anti-inflammatory and cox-2 inhibitory agents: The present invention relates to an anti-inflammatory and COX-2 inhibitory composition that contains at least one of cold-pressed edible seed oils, flours and/or their derivatives having anti-inflammatory and COX-2 inhibitory activity as an active ingredient. The seed oils can be derived from at least one of red raspberry, black raspberry... Agent: Briggs And Morgan P.A.

20070281045 - Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.... Agent: Mcdermott Will & Emery LLP

20070281046 - Method for removing organic contaminants from chinese herb medicines: The present invention relates to the degradation and removal of organochlorine pesticides (OCP) from Chinese herb medicines. In this invention, gamma irradiation is used for the degradation and removal of OCP, such as Pentachloronitrobenzene, Aldrin, Lindane, Heptachlor, Endosulfan-1, Endosulfan-2, o,p′-DDD, p,p′-DDD, p,p′-DDE, and p,p′-DDT from Chinese herb medicines. The method... Agent: Bacon & Thomas, PLLC

20070281048 - Coffee cherry compositions and methods: A cosmetic composition comprises a coffee cherry preparation, and most preferably an extract from a sub-ripe quick-dried coffee cherry. Particularly contemplated cosmetic compositions are formulated as a shampoo, lotion, cream, balm, or ointment, and will have at least one of an antioxidant effect, an anti-inflammatory effect, a UV-protective effect, an... Agent: Fish & Associates, PC Robert D. Fish

20070281047 - Composition containing a plant extract and process for producing same: A composition which includes a pulp extract from the fruit of Argania spinosa and at least one dermopharmaceutical or cosmetic auxiliary and/or additive is provided. A process for producing an extract from the fruit of Argania spinosa, and a triterpene fraction of an extract of the pulp of the fruit... Agent: Cognis Corporation Patent Department